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The Role of Neuroinflammation in Regulating the Age-Related Decline in Neurogenesis 
 
Adam D. Bachstetter 
 
ABSTRACT 
Adult neurogenesis, is a lifelong process by which relatively few cells are added into two 
restricted regions of the brain. Integration of the cells into the existing neuronal circulatory, with 
the unique properties involved in the maturation of these cells, is possibly critical to the 
acquisition and retrieval of new memories. With the chronological aging of the organism a 
process of cellular senescence occurs throughout the body; a portion of which is independent of 
primary alterations to the stem cells; instead, it appears to be dependent on the environment 
where the cells reside, and is in part regulated by inflammation. Microglia, the resident immune 
cells in the brain, are neuroprotective but chronic activation of the microglia, such as the chronic 
activation that occurs with advanced age, can promote neurotoxic inflammation. However, it not 
clear if the aged-related increase in neuroinflammation is at least partly responsible for the aged 
related decrease in neurogenesis. To address the involvement in neuroinflammation in regulating 
neurogenesis we used 3 different potential therapeutically relevant manipulations. The first was a 
targeted approach directed at disrupting the synthesis of Interleukin-1β (IL-1β), which is a 
proinflammatory cytokine that is consistently found elevated in the aged brain. The second was a 
cell therapy approach in which human umbilical cord blood cells were injected into the systemic 
circulation. The final approach was directed at a chemokine system, fractalkine/CX3CR1, which 
has been shown as an important paracrine signal, from neurons that regulates the activation state 
of microglia. While the three approaches used to manipulate, aging-rodent model system were 
different, a consistent finding was reached in all three studies. In the aged brain, microglia which 
are the predominate produces of IL-1β, negatively regulate neurogenesis. When IL-1β is 
decreased or microglia activation is decreased, neurogenesis can be partially restored in the 
aged brain. The results of these studies, demonstrate a key role for microglia in regulating the 
neurogenic neiche, which are amendable to therapeutic manipulations.  
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Introduction 
Aging is the backdrop in which many neurodegenerative disease occur, including Alzheimer's 
disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). As our 
population ages, there is a pressing need to develop therapeutic interventions for age-related 
neurodegenerative diseases. Not only is this true for the patient, but also for the sake of those 
who will care for those suffering from a neurodegenerative disease.  
Alterations in neural plasticity are associated with aging; however, recent studies have 
demonstrated that the age-related alterations in neural plasticity are due to regional synaptic 
alterations and not neuron loss (for review see: (Burke and Barnes, 2006)). One aspect of neural 
plasticity is adult neurogenesis. Adult neurogenesis is the term used for a process, first described 
in 1965, which results in the addition of new neurons in the adult brain (Altman and Das, 1965a). 
The addition of new neurons is complementary to synaptogenesis, and adds another form of 
neural plasticity. Neurogenesis is one of the possible mechanisms that could be utilized, as a 
potential ‘reservoir’ of neural plasticity, to increase the quality of life of our aging population. 
However, it is an important to consider when designing therapeutic strategies for our aging 
population, with and without neurodegenerative diseases, that alterations occur to neural 
plasticity as a result of age, and therefore the response to a therapeutic may be less efficacious in 
the elderly.  
Adult neurogenesis has been found in humans as old as 72 years of age (Eriksson et al., 
1998). However, considerably less is known about adult neurogenesis in humans compare to 
rodents. In rodents, adult neurogenesis has now been extensively studied, and it is now well 
accepted that neurogenesis occurs in at least two germinal centers in the brain, the 
subventricular zone (SVZ) and the subgranlar zone (SGZ) of the hippocampal dentate gyrus (DG) 
(for review see: (Ming and Song, 2005; Zhao et al., 2008)). 
The process of Adult Neurogenesis 
 There are five phases of hippocampal neurogenesis: (1) The first phase is proliferation of 
neural stem/progenitor cells (NPCs) which occurs in a region called SGZ, which is defined as a 
two cell diameter band occurring on the hilus side of the granule cell layer (GCL). (2) The second 
phase is the survival of the proliferating NPCs. During this phase the number of surviving neurons 
can vary greatly depending on the strain of animals used and can be as great as ~ 75% or a few 
as 25% of the amount of proliferating cells (Kempermann et al., 1997a). (3) The third phase, 
occurring in concert with the second phase, is the differentiation of the newly born cells. In this 
phase the majority of cells do become neurons, with a smaller percentage becoming astrocytes 
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and oligodendrocytes. (4) The fourth phase involves migration of the neurons into the GCL; with 
most of the migration occurring around the first week (Kempermann et al., 2003a). (5) Finally, the 
fifth phase involves the functional maturation of the neurons in the granule cell layer which occurs 
around four weeks of age, but some cells may take weeks or even months longer to fully mature 
(van Praag et al., 2002). It has also been demonstrated that those adult born neurons that survive 
after 4 weeks will likely be present at least 11 months later (Kempermann et al., 2003a). The 
majority of the decrease in neurogenesis with age appears to occur mostly in the first phase 
through a decrease in proliferation (Drapeau and Nora Abrous, 2008). Survival of the newly born 
cells appears to be unaffected by age. Maturation of the new born cells, particularly in developing 
a mature neuronal phenotype and migrating into the GCL, does seem to be affected by age 
(Drapeau and Nora Abrous, 2008). 
Non-Cell-Autonomous Changes Regulating Neurogenesis 
In many pathological conditions, including AD and PD, neurogenesis is dramatically affected 
by the pathology (Hoglinger et al., 2004; Verret et al., 2007; Zhang et al., 2007; Nuber et al., 
2008).  Neurogenesis is also  significantly decreased with age (Kuhn et al., 1996; Kempermann et 
al., 2002; Kronenberg et al., 2006a).  The majority of the suppression of neurogenesis with age 
appears to be a function of the microenvironment(niche) and is not NPC autonomous (reviewed 
in:(Zhao et al., 2008). Moreover, the pool of NPCs appears to be intact with respect to the total 
numbers of available NPCs (Hattiangady and Shetty, 2008), providing more evidence that that 
the neurogenic niche is at least partly responsible for the decrease in neurogenesis with age.  
Cellular senescence has been known to occur with age since the 1960s (Hayflick and 
Moorhead, 1961), but the importance of the cellular senescence within the aged stem cell niche 
has only recently become an area of active interest. A clear example of the importance of the 
extrinsic or systemic influences on the stem cell niche was demonstrated in the stem cells that 
are found in the muscle, called satellite cells. Like the neural stem cells, the satellite cells in the 
muscle lose the potential to regenerate damaged tissue with age. In an elegant experiment, when 
aged rats were exposed to the systemic environment of a young rat by parabiosis the satellite 
cells were rejuvenated in the aged rats as demonstrated by an increase in the proliferation rate.  
Conversely, in young rats the exposure to the circulation of the aged rats caused a decrease in 
the regenerative potential of the satellite cells (Conboy et al., 2005), again supportive of an 
extrinsic/circulating factor that is influencing the proliferation of the stem cells in the aged animals. 
It is not clear whether the mechanism involved in the effect in the muscle would hold true in the 
brain, but the implication is that the aged environment is detrimental to stem cell function. This 
also holds true for even the most pluripotent of stem cells: the embryonic stem cells. When 
embryonic stem cells are transplanted into aged tissue they are not able to repair damaged tissue 
as well as when transplanted into young tissue (Carlson and Conboy, 2007). 
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Many changes occur to the aged organisms which are known to negatively impact 
neurogenesis (for review see (Drapeau and Nora Abrous, 2008)). However, there is little known 
about the role of neuroinflammation in regulating the age-related decline in neurogenesis. 
Neuroinflammation is known to negatively impact neurogenesis (Ekdahl et al., 2003; Monje et al., 
2003). It is known that neuroinflammation is elevated in aging and AD (Akiyama et al., 2000; 
Krabbe et al., 2004). The following chapters will begin to clarify the role of neuroinflammation in 
the age-related decline in neurogenesis. 
Inflammation in Aging and Disease 
Inflammation is an active process with the purpose of removing or inactivating potentially 
damaging agents or damaged tissue. The inflammatory response is typified acutely by pain, heat, 
redness, swelling, and loss of function.  Following removal of the ‘danger signal’, a second 
pathway is initiated with the role of tissue remodeling. In the central nervous system (CNS) the 
inflammatory process must be well controlled. Since the majority of the CNS lacks the potential to 
replace lost cells, an inflammatory response could be devastating resulting in neural tissue loss.  
In general, inflammation is a beneficial with the primary result of removing the noxious agent and 
remodeling the adjacent tissue. When inflammation is not well regulated following response to 
‘danger signals’ a chronic pathology will result. It has been clearly shown that in the CNS there is 
a marked increase in inflammatory activity associated with aging (Bodles and Barger, 2004; 
Joseph et al., 2005; Mrak and Griffin, 2005). It is less clear what causes this inflammatory state. 
Cytokines  
Cytokines are low molecular weight proteins, with diverse biological activity due to the 
various target cells and multiple response. Levels of specific cytokines expressed in the brain 
increase as a function of age, even in the absence of a pathologic stimulus. For example, there is 
a progressive increase in the expression of interleukin (IL)-1 and microglia activation with aging in 
patients without a neurological disease (Roubenoff et al., 1998; Wilson et al., 2002), but to a 
lesser extend then in patients with AD (Griffin et al., 1989).  IL-6 levels also increase in the mouse 
brain with advancing age (Godbout and Johnson, 2004).  In the cerebellum of aged rats, tumor 
necrosis factor-α (TNF-α) gene expression is dramatically increased compared to young rats 
(Gemma et al., 2002). Immune response-related molecules and their receptors are expressed 
throughout the brain, and recent research suggests that brain-derived immune factors disrupt 
normal physiology and contribute to cognitive and behavioral dysfunction in neurologic disease 
(Lynch, 1998; Pugh et al., 1999; Rachal Pugh et al., 2001; Barrientos et al., 2002). 
IL-1β 
IL-1β is one of the main inflammatory cytokines found in the CNS involved in 
neuroinflammation (Shaftel et al., 2008). IL-1β is constitutively expressed in the brain, 
synthesized by neuronal and/or glial cells, and released in response to a variety of stimuli, 
including immune system activation (Benveniste, 1992; Rothwell et al., 1997) and in AD (Mrak 
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and Griffin, 2001). IL-1β is a proinflammatory cytokine initially synthesized as an inactive 
precursor that is cleaved by caspase-1 to generate the biologically mature 17-kDa form. In 
rodents the enzymatic activity of caspase-1 is increased with normal aging (Gemma et al., 2005), 
but mRNA expression is not altered (Sheng et al., 2001).  
Virtually every cell type is affected by binding of IL-1β to the high affinity receptor, IL-1RI 
(Rothwell et al., 1997; Dinarello, 1998). The IL-1β receptor expression is high in the hippocampus 
as indicated by binding studies (Farrar et al., 1987; Takao et al., 1990).  The IL-1 family 
comprises three known ligands:  IL-1α, IL-1β and IL-1ra.  The biologic activity of IL-1β is 
dependent on its interaction with IL-1RI and recruitment of the IL-1 receptor accessory protein (IL-
1Racp) (Sims, 2002).  IL-1ra binds to IL-1RI but fails to associate with IL-1Racp, thereby acting 
as a highly selective competitive receptor inhibitor.  The only known function of IL-1ra is to 
antagonize the biologic activity of IL-1. 
IL-1β is a potent suppressor of neurogenesis but it is not completely clear how IL-1β 
achieves this effect. IL-1β has been shown in vitro to be able to induce apoptosis in NPCs via 
phosphorylation of the stress-activated protein kinase/Jun-amino-terminal kinase (SAPK/JNK) 
pathway (Wang et al., 2007), thereby having a direct effect on the survival of the new born 
neurons. The NF-κB/Iκκ pathway also seems to be critical in regulating the effects of IL-1β on 
proliferation, possibly by decreasing Cyclin D1 expression (Koo and Duman, 2008).  IL-1β, in 
NPCs cultures also seemed to slightly favor differentiation into an astrocyte linage as determined 
by the marker GFAP (Wang et al., 2007).  
IL-1β is not alone in being able to directly affect NPC. Recently, Iosif et al. (2006) has 
shown that the inflammatory cytokine TNF-α can also assert a direct effect on NPC proliferation. 
TNF receptor 1 (TNF-R1) appears to have a regulatory function by blocking proliferation during 
inflammation. This action occurs directly at the progenitor cells which express both TNF-R1 and 
TNF-R2. TNF-R2 appears to play a neuroprotective role; although, its function is a little less clear 
than that of TNF-R1 (Iosif et al., 2006).  
Chemokines 
Chemokines are small molecule (8-14 kDa) proteins that are classically defined as 
chemotactic cytokines initially studied because of their role in leukocyte trafficking. Chemokines 
are classified into 4 subfamilies – C; CC; CXC and CX3C – by the position of the conserved 
cysteine residues near the NH2 terminus region of the protein (Bacon et al., 2002). The receptors, 
by which chemokines exert their effects, are of the seven-transmembrane-domain G-protein-
coupled receptor (GPCR) family.  Chemokine GPCRs belongs to the class A rhodopsin-like 
family, with the majority of the receptors being Gαi as indicated by the ability of pertussis toxin 
(PTX) to inhibit the response of the receptors (Murphy, 1996). The extracellular NH2 terminus and 
the three extracellular loops act to bind the chemokine ligand. The three intracellular loops and C-
terminus act in signal transduction (Mellado et al., 2001).  
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Fractalkine/CX3CR1 
In contrast to many other chemokines, fractalkine (FKN; CX3CL1; neurotactin) binds and 
activates a single receptor, CX3CR1. Interactions between FKN and CX3CR1 contribute to 
maintaining microglia in a resting phase, and partially controlling microglia induced neurotoxicity 
(Cardona et al., 2006).  FKN acts in vitro as an anti-inflammatory molecule by down-regulating IL-
1β, TNF-α, and IL-6 production (Zujovic et al., 2000; Zujovic et al., 2001). FKN can therefore, act 
as a bridge between neurons and microglia, to regulate cytokine production and 
neuroinflammation.  
FKN is the only known member of the CX3C chemokine family (Bacon et al., 2002). FKN 
is unique among chemokines; with cell surface presentation of the N-terminal chemokine domain 
by a glycolated mucin-like stalk, that is anchored to membrane with a transmembrane and C-
terminal cytoplasmic domain (Bazan et al., 1997; Pan et al., 1997). The chemokine domain can 
be shed from the mucin stalk by a constitutive expressed metalloproteinase 10 (ADAM10) 
(Hundhausen et al., 2003), or by an inducible cleavage by TNF-a converting enzyme (TACE / 
ADAM17) (Garton et al., 2001). FKN is not expressed on peripheral blood leukocytes (Bazan et 
al., 1997; Pan et al., 1997). FKN is expressed on endothelial cells(Bazan et al., 1997), epthelial 
cells (Lucas et al., 2001), smooth muscle cells (Ludwig et al., 2002), dendritc cells (Papadopoulos 
et al., 1999) and neurons (Pan et al., 1997; Harrison et al., 1998). FKN is most robustly 
expressed in the CNS (Harrison et al., 1998). In isolated primary cultures neurons RT-PCR 
showed FKN mRNA to be highest in neurons; however, low levels were detected in microglia and 
astrocytes (Nishiyori et al., 1998).  
In the CNS, FKN is predominantly expressed on neurons and is one of only two 
chemokines that is constitutively expressed by neurons, the other being stromal cell-derived 
factor-1 (SDF-1; CXCL12). SDF-1 is monomeric like FKN (Crump et al., 1997; Mizoue et al., 
1999). Recently it has been shown that SDF-1 has an important role in directly regulating adult 
neurogenesis (Bhattacharyya et al., 2008; Kolodziej et al., 2008). It is not currently know if FKN 
might have a similar role in regulating neurogenesis.  
FKN also has a higher affinity for its receptor (CX3CR1) then other chemokine receptor 
ligand pairs (Haskell et al., 2001). The exclusive receptor for FKN is a PTX sensitive GPCR, 
named CX3CR1. Predominate expression of CX3CR1 in the CNS is found on microglia, which 
suggest a paracrine regulation of microglia by neurons (Harrison et al., 1998). However, 
expression of the receptor, is not sufficient to determine activity following ligation. In CD14+ 
moncoctyes less then 2% of cells that express CX3CR1 migrated to soluble FKN (Imai et al., 
1997). Moreover, of all the CX3CR1+ cells only 10% of the cells became activated after exposure 
to soluble FKN (Imai et al., 1997). The adhesion properties of FKN appear to be independent of 
signaling via the GPCR as PTX was no effect on adhesion (Imai et al., 1997).  
The expression of CX3CR1 includes a subset of dendritic cells and natural killer cells, 
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peripheral blood monocytes and tissue macrophages including microglia (Jung et al., 2000). In 
the CNS, CX3CR1 expression in vivo is limited to immune cells, namely microglia and not 
astrocytes or neurons (Cardona et al., 2006; Combadiere et al., 2007). However, CX3CR1 
expression has been shown in cultured neurons. Moreover, in vitro, FKN via CX3CR1 was able to 
reduce excitotoxic cell death induced by glutamate and neurotoxicity induced by gp120IIIB +, an 
HIV envelope glycoprotein (Meucci et al., 2000; Tong et al., 2000; Limatola et al., 2005). 
Recent evidence has shown a role for CX3CR1 polymorphisms in the pathogenesis of 
age-related macular degeneration (Tuo et al., 2004; Combadiere et al., 2007). There are at least 
two common coding polymorphsims, V249I and T280M, in the CX3CR1 gene (Faure et al., 2000; 
McDermott et al., 2001; Moatti et al., 2001), as well as, a single nucleotide poymorphims in the 
promoter region of CX3CR1 (DeVries et al., 2003). The two SNPs CX3CR1 with a strong linkage 
disequilibrium include: (1) A SNP at condon 249 that causes a switch from valine to isoleucine 
(V249I). The other SNP results in a switch from threonine to methionine at codon 280 
(T280M). The M280/I249 variant caused reduced function of the receptor, including decreased 
adhesion, signaling and chemotaxis (McDermott et al., 2003). The M280/I249 variant is also 
associated with reduced risk for atherosclerosis. Moreover, in aged CX3CR1-/-  but not in aged 
CX3CR1+/+ or young CX3CR1-/-  there was in age-related accumulation of microglia that led to 
retinal neurodegeneration in the CX3CR1-/- (Combadiere et al., 2007).  
 FKN/CX3CR1 signaling has been shown to be neuroprotective in a number of brain 
injury models (Cardona et al., 2006). The neuroprotective role of CX3CR1 has recently been 
questioned in a model of focal cerebral ischemia where CX3CR1-/- mice had a worse outcome 
following the transient middle cerebral artery occlusion (MCAO) whereas, FKN-/-  mice had 
improved outcome following MCAO (Soriano et al., 2002; Denes et al., 2008). The results of this 
study may not disprove the role of CX3CR1 in neuroprotection, but instead provide more 
supporting evidence of the diverse role of microglia and macrophages. Following a short dramatic 
neuronal insult, such as an MCAO, a more robust early immune response may be protective to 
the insult. This is in comparison to a prolonged neurodegenerative condition such as AD or PD. 
Moreover, as the blood brain barrier (BBB) is broken by the MCAO a different complement of 
immune cells may be recruited to the injury compared to a neurodegenerative condition with an 
intact BBB. 
Microglia 
Microglia are always surveying the microenvironment, and once they sense the 
appropriate signals such as neuronal damage the cells will hone to the site of damage (Davalos 
et al., 2005; Nimmerjahn et al., 2005). As the resident innate immune cells in the CNS, microglia 
constitutively express surface receptors that trigger or amplify the innate immune response, 
including toll-like receptors, complement receptors, cytokine receptors, chemokine receptors, 
major histocompatibility complex (MHC) II, and others (Aloisi, 2001). The main cell type in the 
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CNS that is responsible for immunity is the microglia. Lipopolysaccharides (LPS) is an endotoxin 
that is part of the outer membrane of gram-negative bacteria. LPS up-regulates the production of 
IL-1β by microglia (Lee et al., 1993). Cytokines such as IL-1β, and TNF-α can also act in an 
autocrine or paracrine manner to increase the production of IL-1β by microglia (Lee et al., 1993). 
Astrocytes can also be stimulated by IL-1β, but not by LPS, to produce TNF-α and IL-6. However, 
the production of cytokines by astrocytes is less than that of microglia (Lee et al., 1993). 
Therefore, while astrocytes and neurons can make inflammatory mediators, the microglia are the 
main source of inflammatory cytokines (Aloisi, 2001). 
However, the role of microglia is not destructive. Upon detection of homeostatic 
disturbance, microglia rapidly respond by inducing a protective immune response. The protective 
immune response begins with a transient upregulation of inflammatory molecules, including 
proinflammatory cytokines, such as TNF-α, IL-1, and  IL-6 and IL-12 (Gao et al., 2002; Mantovani 
et al., 2004). This is followed by a protective phase that is immunomodulatory and 
neuroprotective. The protective phase includes neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and insulin-like 
growth factor 1 (IGF-1) (Miwa et al., 1997; Batchelor et al., 1999; Nakajima and Kohsaka, 2004). 
Thus, microglia remove cells damaged from acute injury and protect CNS functions. 
Microglia are neither pro-neurogenic or anti-neurogenic but their influence on 
neurogenesis is dependent on their activation state of either ‘classically’ activated or ‘alternatively’ 
activated (Battista et al., 2006; Butovsky et al., 2006b) (figure 1). Much like what has been 
proposed for peripheral macrophages, microglia are very pleiotropic. Microglia, can become 
‘classically’ activated as defined by the release of pro-inflammatory cytokines (e.g. TNF-α and IL-
1β) (Giulian et al., 1986; Griffin et al., 1989). Once in this ‘classically’ activated, pro-inflammatory 
state, microglia are associated with further production of these pro-inflammatory cytokines, ROS, 
chemokines, and matrix metalloproteases, resulting in cell death of invading cells and tissue 
destruction, and type-I inflammation (Mantovani et al., 2007). A second type of microglia are 
those that are activated by such things as IL-4 and TGFβ, and are called ‘alternatively’ activated 
or in an ‘M2’ state (following the TH1/TH2 classification of T-helper cells) (Mantovani et al., 2007). 
Compare to the ‘M1’ or ‘classically’ activated state, microglia in the ‘M2’ state can be protective 
(Mantovani et al., 2004).  When microglia are in this ‘M2’ state there is little release of pro-
inflammatory cytokines and they are resistant to activation by agents such as LPS (Mantovani et 
al., 2007). Alternatively activated macrophages promote extracellular matrix formation and 
angiogenesis (Mantovani et al., 2007). A third type of microglia is one that becomes dysfunctional 
with age. The senescent microglia are not able to respond appropriately to stimuli and may 
exacerbate neuroinflammation (Schwartz et al., 2006a; Streit, 2006a). Isolated microglia from 
aged mice have elevated basal expression of TNF-α, IL-1β, IL-6, and TGFβ1 (Sierra et al., 2007). 
When stimulated the mice were stimulated with LPS, the isolated microglia from aged mice 
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produced more of the proinflammatory cytokines TNF-α, IL-1β, IL-6, then the young LPS 
stimulated mice, but the LPS fold change in cytokine production in aged mice was equal to that in 
young mice. Therefore, microglia from aged animals can respond to an inflammatory challenge 
the same as young mice, but the baseline of cytokine expression is elevated (Sierra et al., 2007). 
Age Related Alterations in Adaptive Immunity  
There is also a decrease in immunological function in the periphery (Miller, 1996; 
Goronzy and Weyand, 2005). It appears that the age of the T-cell when it first encounters an 
antigen will determine if a memory response is achieved. For example, T-cells from aged rats 
were able to maintain memory function acquired when they were young, but were not able to 
acquire new memory formation; this was most likely due to a lack of proliferative ability (Haynes 
et al., 2003). Furthermore, aged naïve CD4 T-cells could be stimulated by exogenous IL-2 to 
induce memory, but once the IL-2 was removed the memory was lost (Haynes et al., 2003). Even 
as most T-cell function declines with age, the CD4+CD25+ T regulatory (Treg) cells are still able to 
suppress the activity of young CD4+CD25- T helper (Teff/Th) (Nishioka et al., 2006). Even more 
important, the CD4+CD25- T-cells not only become unresponsive with age they also become 
suppressive limiting the immune response (Shimizu and Moriizumi, 2003).   
The CNS does have a reservoir to drain antigen in the cervical lymph nodes (Cserr and 
Knopf, 1992). The recruitment of leukocytes can also take place in postcapillary venules (Hickey, 
2001). It has been shown that there are changes to structure and function of the blood-brain-
barrier (BBB) as a result of age, which causes an increase in permeability (Mooradian, 1988, 
1994; Morita et al., 2005). Normally, in a young adult in the absence of disease, there is a clear 
demarcation between the peripheral immune system, innate and adaptive, and the CNS immune 
system with its ‘lone sentinel,’ the microglia.  
Following an acute stimulation such as a traumatic injury or ischemia, the protective 
status of the CNS is revoked and peripheral immune cells (dendritic cells and T-cells) can enter 
into the CNS. The consequences of the invading peripheral immune cells are to either, clear 
debris and rebuild damaged tissue or exacerbate the injury. T-cells can be involved in governing 
the immune response (Kim et al., 2007). T-cell response may act by altering the activity of the 
microglia and this response is important to maintain neurogenesis (Kipnis et al., 2004; Butovsky 
et al., 2006a; Butovsky et al., 2006b; Schwartz et al., 2006a) 
 Injury is not the only time that this immune privilege is revoked, in aging you can also 
find invasion of T-cells and dendritic cells (Stichel and Luebbert, 2007). Occurring as early as 12 
months of age in rats, dendritic cells and T-cells can be found in the brain. These peripheral 
immune cells, which are absent in young adult rats, are found widely distributed throughout the 
aged rat brain, and are particularly associated with white matter tracks (Stichel and Luebbert, ; 
Bulloch et al., 2008).  What causes this invasion of peripheral immune cells is not entirely known.  
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The increase of microglia presenting antigen, as shown by expression of major 
histocompatibility complex Class II (MHC II), as well as, an increase in the peripheral immune 
systems professional antigen presenting cells (dendritic cells) in the aged brain, may be a useless 
response as the T-cells don’t appear able to respond to the antigen. The presentation of antigen 
to T-cells by APCs is futile, as the T-cells do not appear able to respond to the antigen. The lack 
of an immune response appears to lead to tolerance of T-cells and continued activation of APC, 
and this futile response could be producing a positive feedback loop of chronic inflammation. 
Human Umbilical Cord Blood Cells as a Potential Therapeutic  
The mononuclear fraction of human umbilical cord blood (HUCB) contains a number of cell 
types including, B-Cells, and T-Cells, monocytes, as well as, mesenchymal and endothelial 
progenitor cells. HUCB is also a source of CD34+ hematopoietic stem cells (Bender et al., 1991; 
Ho et al., 1996; Wu et al., 1999). HUCB cells, particularly the CD34+ stem cells, have in animal 
models of stroke provided multiple benefits adding in the function recovery after the infarct (Chen 
et al., 2001; Saporta et al., 2003; Willing et al., 2003; Taguchi et al., 2004; Vendrame et al., 2004; 
Vendrame et al., 2005; Vendrame et al., 2006b) While HUCB CD34+ stem cell have the potential 
to differentiate into neurons in vitro, when these cells are transplanted into the brain few survive. 
Previously immunohistochemical analysis directed towards a human nuclear antigen (HuNu) has 
found few HuNu positive cells surviving after the transplant and the small number of surviving 
HUCB cells in the brain rules out a direct replacement of the lost cells as a mechanism for the 
beneficial effects of HUCB cells (Chen et al., 2001; Vendrame et al., 2004). Taguchi et al. (2004) 
showed that some of the functional recovery after stroke provided by CD34+ cells was due to 
enhancement of both neurogenesis and angiogenesis (Taguchi et al., 2004). The article by 
Taguchi et al. (2004) is concerned with the neurogenesis occurring post-stroke in regions of the 
brain considered non-neurogenic (Taguchi et al., 2004). 
The effects of HUCB seem to be due to a regulation of the microenvironment of the brain, 
through releasing tropic factors or reducing inflammation and not by direct replacement of cells. It 
was recently demonstrated that a systemic injection of HUCB cells could suppress inflammation 
in the brain inflammatory response after stroke. Moreover, the effects of HUCB cells seemed to 
shift the cytokine expression from a Th1 response to a Th2 response (Vendrame et al., 2004; 
Vendrame et al., 2005; Vendrame et al., 2006b). Besides the immune modulatory effects, HUCB 
cells also produce a number of trophic factors including but not limited to, vascular endothelial 
growth factor, nerve growth factor, and cytokine colony stimulating factor-1, thrombopoietin, and 
IL-11 (Suen et al., 1994; Taguchi et al., 2004; Vendrame et al., 2004). 
Conclusion 
 Neurogenesis is an important means of neural plasticity that is diminished with increasing 
age. Neurogenesis from endogenous NPC may provide an alternative to transplantation of stem 
cells as a means to replace damaged neural tissue after brain injury, such as stroke, or as a 
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result of a neurodegenerative condition. A growing body of research shows that neurogenesis 
may occur in ‘non-neurogenic’ regions as a result of a stroke or neurodegenerative disease 
(Kokaia and Lindvall, 2003). There is also the hope of recruiting neural stem cells, from the 
neurogenic regions of the brain to replace damaged cells after injury (Bernal and Peterson, 
2004). Before either strategy of using neurogenesis as a therapeutic source of new cell can be 
implemented, a better understanding of the regulation of neurogenesis is necessary. 
During aging and exacerbated in AD, a state of chronic inflammation occurs (Bodles and 
Barger, 2004; Joseph et al., 2005; Mrak and Griffin, 2005). Inflammation, while not the only cause 
for the decrease in neurogenesis with age, is very important in regulating neurogenesis (Ekdahl 
et al., 2003; Monje et al., 2003). To harness the potential of neurogenesis to help in brain repair a 
better understanding of the mechanism of how inflammation is regulating neurogenesis is 
necessary. While a loss of trophic factors and increased corticosteroids are important contributors 
to the aged niche and have been extensively reviewed (Drapeau and Nora Abrous, 2008) the 
focus of following chapters of this dissertation are limited to the role of inflammation in regulating 
stem cell function in the aged neurogenic niche.  
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Fig.1. Microglia: protective or harmful? Microglia are normally in a resting state in which they 
are actively surveying the microenvironment of the brain. The microglia are resting in the sense 
that they are not performing effector functions such as producing inflammatory mediators like IL-
1β and TNFα. When microglia are producing inflammatory mediators the microglia would be 
considered in a ‘classically activated state or ‘TH1’ state. Microglia can also become ‘alternatively 
activated’ in such a way that they produce growth factors, such as IGF-1 and TGFβ. The 
‘alternatively activated’ microglia can support tissue remodeling and repair. Beyond releasing 
signaling molecules, microglia also have an important role in phagocytosis. The role of microglia, 
as protective or harmful, depends upon the ability of the microglia to switch from the different 
activation states at the appropriate time. Understanding how and when to turn microglia ‘on’ or 
‘off’ is an important future direction of research. This is especially the case with aging where 
microglia are most need for remodel and repair and to remove damaged cells and misfolded 
proteins. With age microglia may lose the ability to perform these important effector functions 
making the aged brain more susceptible to injury and insult.  
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Abstract 
Adult hippocampal neurogenesis dramatically decreases with increasing age, and it has 
been proposed that this decline contributes to age-related memory deficits.  Central inflammation 
contributes significantly to the decrease in neurogenesis associated with aging.  Interleukin-1β is 
a proinflammatory cytokine initially synthesized as an inactive precursor that is cleaved by 
caspase-1 to generate the biologically active mature form.  Whether IL-1β affects neurogenesis in 
the aged hippocampus is unknown.  Here we analyzed cells positive for 5`-bromo-deoxy-uridine 
(BrdU, 50 mg/kg) in animals in which cleavage of IL-1β is inhibited by the caspase-1 inhibitor Ac-
YVAD-CMK (10 pmol).  Aged (22 mo) and young (4 mo) rats received Ac-YVAD-CMK for 28 d 
intracerebroventricularly through a brain infusion cannula connected to an osmotic minipump.  
Starting on day 14, animals received a daily injection of BrdU for 5 consecutive days.  Unbiased 
stereology analyses performed 10 d after the last injection of BrdU revealed that the total number 
of newborn cells generated over a 5-d period was higher in young rats compared to aged rats.  In 
addition, there was a 53% increase in the number of BrdU-labeled cells of the aged Ac-YVAD-
CMK- treated rats compared to aged controls.  Immunofluorescence studies were performed to 
identify the cellular phenotype of BrdU labeled cells.  The increase in BrdU-positive cells was not 
due to a change in the proportion of cells expressing neuronal or glial phenotypes in the 
subgranular zone.  These findings demonstrate that the intracerebroventricular administration of 
Ac-YVAD-CMK reverses the decrease in hippocampal neurogenesis associated with aging.  
Introduction 
Neurogenesis occurs throughout life, predominantly in the subgranular zone (SGZ) of the 
dentate gyrus in the hippocampal formation and in the subventricular zone (SVZ) (Altman and 
Das, 1965b; Cameron et al., 1993; Eriksson et al., 1998; Gage, 2002; Lie et al., 2004; Mackowiak 
et al., 2004; Christie and Cameron, 2006). Neural stem cells in the SGZ give rise to progenitor 
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cells that migrate into the granule cell layer and differentiate into neuronal or glial phenotypes.  
Newly generated hippocampal granule cells acquire the morphologic and biochemical properties 
of neurons, develop synapses on their cell bodies and dendrites, and extend axonal projections 
along mossy fibers into the hippocampal CA3 region (Hastings and Gould, 1999; Markakis and 
Gage, 1999; Carlen et al., 2002). These newly generated granule neurons are electrically active, 
fire action potentials, and receive synaptic input (Cameron and McKay, 2001; van Praag et al., 
2002; Schmidt-Hieber et al., 2004; Overstreet-Wadiche et al., 2006; Overstreet-Wadiche and 
Westbrook, 2006) and survive for an extended period of time (Altman and Das, 1965b). 
A multitude of factors have been shown to regulate the production of new neurons in the 
adult hippocampus.  For example, the rate of neurogenesis decreases with increasing age (Seki 
and Arai, 1995; Kuhn et al., 1996; Lichtenwalner et al., 2001; Bizon and Gallagher, 2003). 
Several lines of evidence suggest a correlation between adult neurogenesis and learning, and it 
has been proposed that a decline in hippocampal neurogenesis contributes to a physiologic 
decline in brain function (Gould et al., 1999b; Ambrogini et al., 2000; Kempermann and Gage, 
2002; Bizon and Gallagher, 2003; Drapeau et al., 2003; Leuner et al., 2004; Bruel-Jungerman et 
al., 2005). New and important insights as to the production of new neurons may affect 
hippocampal-dependent memory ability have been provided by behavioral experiments 
performed using the Morris water-maze task, which is a hippocampal-dependent memory task 
used to analyze spatial memory.  The learning performance in the water-maze task is 
characterized by two consecutive phases: an early phase during which the learning performance 
reaches 80% and a late phase during which the learning performance decreases to 20% after 
which a stable baseline is reached.  Importantly, it has recently been shown that spatial learning 
in both young and aged rats increases the survival of cells generated before the learning (Gould 
et al., 1999b)but decreases the survival of cells born during the early phase of learning (Lemaire 
et al., 2000; Shors et al., 2001; Dobrossy et al., 2003; Drapeau et al., 2007). Thus, it seems that 
the new born cells generated before training may be at the critical period of sensitivity to be 
rescued by learning.  On the other hand, cells generated during the early phase of learning may 
be too young to be rescued.  
In rats, numerous conditions that increase adult hippocampal neurogenesis are 
associated with an increase in learning performance (Luine et al., 1994; de Quervain et al., 1998; 
Bizon and Gallagher, 2003; Drapeau et al., 2003; Mirescu and Gould, 2006). For example, 
decreases in glucocorticoid levels, which are elevated in aged rats, increases neurogenesis 
(Gould et al., 1998) and spatial memory in the water-maze (Drapeau et al., 2003). Furthermore, 
injection of N-methyl-D-aspartate receptor antagonists into aged rats significantly improves 
memory deficits and increases neurogenesis (Cameron et al., 1995; Nacher et al., 2001; Nacher 
et al., 2003; Nacher and McEwen, 2006; Nacher et al., 2007). Finally, insulin-like growth factor, 
fibroblast- growth factor -2, and endothelial-growth factor decrease with aging, and administration 
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of these trophic factors increases neurogenesis in the hippocampus (Beck et al., 1995; O'Kusky 
et al., 2000; Cheng et al., 2001; Zaman and Shetty, 2002). Likewise, an enriched environment, 
exercise , and caloric restriction or dietary supplementation with blueberries improve age-related 
memory deficits and increase neurogenesis (Paylor et al., 1992; Kempermann et al., 1997b, 
1998; van Praag et al., 1999; Kempermann et al., 2002; Casadesus et al., 2004; Olson et al., 
2006). These observations suggest that the age-related decrease in neurogenesis is due to a 
global, age-related alteration in the microenvironment of the brain.  Recent reports indicate that 
brain inflammation negatively influences adult hippocampal neurogenesis (Ekdahl et al., 2003; 
Monje et al., 2003). Intracortical infusion of lipopolysaccharides (LPS), a potent activator of the 
inflammatory response, induces an 85% reduction in the number of new neurons in the dentate 
gyrus SGZ (Ekdahl et al., 2003; Monje et al., 2003). Systemic administration of minocycline, 
which inhibits microglial activation, restores LPS-induced decreases in neurogenesis.  In addition, 
tumor necrosis factor α (TNFα) is involved in the regulation of adult hippocampal neurogenesis 
(Iosif et al., 2006). Interleukin-1 β (IL-1 β) is a proinflammatory cytokine involved in the 
pathogenesis of several acute and chronic neurodegenerative diseases.  There is extensive 
evidence that IL-1β is constitutively expressed in the brain, synthesized by neuronal and/or glial 
cells, and released in response to a variety of stimuli, including immune system activation 
(Benveniste, 1992; Rothwell et al., 1997). High brain levels of IL-1β are also correlated with 
natural aging and the development of cognitive dysfunction (Rachal Pugh et al., 2001; Lynch, 
2002; Yirmiya et al., 2002). For example, contextual fear conditioning, a hippocampal-dependent 
memory task, is impaired in aged rats, and administration of a nonsteroidal anti-inflammatory 
drug, sulindac, reversed the impairment and decreased IL-1β levels (Mesches et al., 2004). 
Almost every cell type is affected by IL-1β acting through its high - affinity receptor, IL-1RI 
(Rothwell et al., 1997; Dinarello, 1998).  Binding studies indicate that the hippocampus contains 
the highest density of IL-1β binding sites (Farrar et al., 1987; Takao et al., 1990). Interleukin-1β is 
synthesized as an inactive precursor that is cleaved by the protease caspase-1 to generate the 
mature 17kDa form.  Caspases are a family of proteases that have a critical role in apoptosis and 
inflammation and are also implicated in cognition.  The caspase family includes inflammatory 
caspases (caspase-1, 4, 5, 11, and 12), initiator caspases (2, 8, 9, and 10), and executioner 
caspases (caspase-3, 6, and 7).  Caspase-1 (IL-1β converting enzyme) is constitutively 
expressed in macrophages and microglia and is involved in the activation of both apoptosis and 
inflammation through the production of IL-1β.  Caspase-1 inhibition has shown extraordinary 
promise in multiple disease models.  For example, in cerebral ischemia, caspase-1 is 
neuroprotective by reducing apoptosis and decreasing the production of proinflammatory 
cytokines (Rabuffetti et al., 2000). Recently, we demonstrated that caspase-1 inhibition 
significantly improves hippocampal-dependent contextual memory function by inhibiting IL-1β, 
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TNFα, and caspase-3 activity in the hippocampus (Gould et al., 1999b). Here we demonstrate 
that inhibition of caspase-1 activity increased hippocampal neurogenesis in the aged brain.   
Material and Methods 
Animals. All experiments were performed in accordance with the National Institutes of 
Health Guide and Use of Laboratory Animals.   
Surgical procedure and treatments. The study used male Fischer 344 rats (NIA 
contract colony, Harlan Sprague Dawley, Indianapolis, IN).  Rats were housed in pairs and 
maintained in environmentally controlled chambers on a 12:12-h light-dark cycle at 21 ± 1 ºC.  
Food and water were provided ad libitum.  We used groups of 8 aged (20 mo) or 8 young (4 mo) 
rats (4 subgroups = old caspase -1 inhibitor (Ac-YVAD-CMK), old controls, young Ac-YVAD-CMK, 
young controls).   The rats were implanted intracerebroventricularly (icv) with a brain infusion 
cannula in the left lateral ventricle and an osmotic minipump (Alzet, Model 2004 pumping rate, 
0.25 µl/h; total volume 200 μl) for 28 d.  Before implantation, the pumps were incubated in sterile 
saline for at least 48 h at 37°C to prime the pumps.  For implantation, rats were anesthetized with 
isofluorane and placed into a stereotaxic frame.  A guide cannula was stereotaxically implanted in 
the left ventricle (AP = -1.0 mm; ML = 1.6 mm, DV = -3.5) and connected to the osmotic 
minipump, which was inserted subcutaneously.  Pumps were weighed before implantation and at 
the end of the experiment to ensure complete delivery of their content.  The caspase-1 inhibitor, 
Ac-YVAD-CMK (10 pmol/200 μl; Calbiochem, La Jolla, CA), was injected (0.25 μl/h) through the 
cannula which was connected to the filled minipump.  The infusion started the day of the surgery 
and continued for 28 d. Control animals received the same volume of 0.6% DMSO (Sigma 
Aldrich, St. Louis, MO) in saline.  Rats received a daily injection of BrdU (Sigma; 50 mg/kg) once 
a day for 5 d beginning on 14 d after surgery.  Rats were sacrificed 10 d following the last 
injection of BrdU (28d post-surgery).  Rats were then perfused transcardially with saline followed 
by 4% paraformaldehyde in PBS.  The brains were removed and postfixed overnight and then 
moved to 30% sucrose in PBS prior to sectioning on a cryostat. 
BrdU staining procedure: Cryostat sections were cut in the sagittal plane (40μm), 
collected in a cryoprotectant solution (30% ethylene glycol, 30% glycerol in 0.01 M PBS), and 
stored at –20 ºC until processed.  In preparation for an unbiased stereologic estimate of neuronal 
numbers, an initial tissue section was selected randomly at one anatomic border of the brain 
region to be examined.  Thereafter, every 3rd section throughout the anatomic region of interest 
was used for each staining series.  For the immunohistochemistry staining procedure, selected 
sections were floated individually in plastic multiwell carriers with nylon net bottoms.  Free-floating 
sections (40 µm) were pretreated with 50% formamide/2X SSC (0.3 M NaCl, 0.03 M sodium 
citrate) at 65°C for 2 h, rinsed in 2X SSC, incubated in 2 N HCL for 30 min at 37°C, and washed 
with borate buffer (pH 8.5).  After washing with PBS three times, endogenous peroxidase activity 
 16
was quenched by incubating in 0.3% H2O2 solution, followed by a 1- h incubation in blocking 
solution (0.1 M PBS supplemented with 3% normal horse serum and 0.25% Triton X-100).  
Sections were then incubated overnight with mouse-anti-rat-BrdU (1:50; Roche) in PBS 
supplemented with 3% normal horse serum and 0.1% Triton X-100.  Sections were washed and 
biotinylated secondary antibody (1:200; Vector Laboratories, Burlingame, CA) in PBS 
supplemented with 3% normal horse serum and 0.1% Triton X-100 was applied for 1 h.  The 
sections were incubated for 60 min in avidin-biotin substrate (ABC kit, Vector Laboratories).  All 
sections were incubated for 3 min in DAB solution (Vector Laboratories). Sections were mounted 
onto glass slides and coverslipped with mounting medium.  
OX-6 staining procedure: Immunohistochemistry was performed on every six section 
throughout the dentate gyrus.  Free-floating sections were processed individually for 
immunoreactivity to the MHC Class II Ia antibody OX-6 in plastic 24-well plates (Corning, Inc., 
Corning, NY).  Sections were rinsed in 0.1 M PBS, pH 7.4.  Three 5-min washes were conducted 
between steps except where indicated.  Control sections not exposed to primary or secondary 
antibodies were prepared simultaneously.  After equilibrating tissue sections in washing solution, 
endogenous peroxidase activity was quenched by incubating the sections in 0.1M PBS containing 
0.3% H2O2 for 15 min.  Background labeling was blocked by 1 h incubation in PBS containing 
10% normal horse serum and 0.05% TX-100.  Sections were then incubated overnight with 
mouse-anti-rat- OX-6 (Pharmingen, San Diego, CA; 1:750) in PBS containing 3% horse serum 
and 0.025% TX-100.  After incubation in primary antibody, the sections were washed and 
incubated for 60 min in biotinylated horse anti-mouse secondary antibody (Vector Laboratories, 
Burlingame, CA; 1:300) diluted in washing solution containing 3% normal horse serum and 0.3% 
TX-100.  Sections were then incubated for 90 min in avidin-biotin “ABC Elite” substrate (Vector 
Laboratories, Burlingame, CA).  The sections were then rinsed three times for 10 min each in 
PBS.  Color development was performed in a standardized manner such that all sections were 
developed in the same reagents for identical periods of time to allow for comparisons of fiber 
staining intensity.  All sections were incubated for 3 min in diaminobenzidine solution (Vector 
Laboratories).  Sections were mounted onto glass slides and cover - slipped with aqueous 
mounting medium.   
Stereology.  BrdU cells were examined with a Nikon Eclipse 600 microscope and 
quantified using Stereo Investigator software, Version 6 (MicroBrightField, Colchester, VT).  Cells 
were counted within two cell diameters below the SGZ  using the optical fractionator method of 
unbiased stereologic cell counting (West et al., 1991). The sampling was optimized to count at 
least 250 cells per animal with error coefficients of less than 0.07. Each counting frame (75 x 75 
μm) was placed at an intersection of the lines forming a virtual grid (100 x 100 μm), which was 
randomly generated and placed by the software within the outlined structure.   
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Stereologic estimation of the total number of OX-6 immunolabeled cells: The 
dentate gyrus was outlined and analyzed. OX-6 positive cells in the dentate gyrus were counted 
using the optical fractionator method of unbiased stereologic cell counting techniques.  Optical 
disectors were 100μm x 100μm.  The sampling was optimized to sample at least 150 counted 
cells per animal.  Each counting frame was placed at an intersection of the lines forming a virtual 
grid (200μm x 200 μm) that was randomly generated and randomly placed by the software within 
the outlined structure.  OX-6 - labeled cells were counted using a 60X oil lens (NA 1.4) and were 
included in the measurement only when they came into focus within the disector (disector height 
of 20 µm and the average thickness of mounted sections was 30 µm; thickness was measured at 
random intervals throughout every section and estimated by the software program).   
Immunofluorescence procedure: Immunofluorescence double labeling was performed 
to determine the phenotype of BrdU positive cells. Tissues were pretreated with 2 N HCL for 2 h 
at room temperature, washed, and incubated in blocking solution (0.1 M PBS containing 10% 
goat serum and 0.3% Triton X-100) for 1 h at room temperature.  Tissues were then incubated in 
rat anti-BrdU (1:400; Accurate Chemical, Westbury, NY) overnight at 4°C. Tissues were rinsed 
three times in PBS and goat anti-rat secondary antibody conjugated to Alexa 594 (1:800; 
Molecular Probes, Eugene, OR) was applied for 1 h.  Following 6 washes, one of the following 
primary antibodies was applied overnight at 4°C: rabbit anti-GFAP (1:500; Dako, Carpinteria, CA), 
mouse anti-NeuN (1:100; Chemicon, Temecula, CA), TuJ1 (1:800; Covance), rabbit cleaved 
caspase -3 (1:100; Cell Signaling, Danvers MA).  Tissues were washed three times with PBS and 
species-appropriate secondary antibody conjugated to Alexa 488 (Molecular Probes) was applied 
for 2 h at a 1:200 dilution (anti-GFAP secondary was applied for 1 h at a dilution of 1:800).  
Following six washes in PBS, tissues were mounted on slides and coverslipped using Vectashield 
(Vector Labs).  To calculate the percentage of each phenotype with respect to the number of 
BrdU-labeled cells, the total number of BrdU-labeled cells and their respective phenotypes for 
each animal were scored in at least six or more sections of a one-in-six series.  The results from 
each section were summed, and the percentage for each marker was calculated. These 
percentages were then expressed as the average of 4 to 6 animals.  Colocalization of BrdU-
positive cells with GFAP, TuJ1, NeuN, and caspase-3 was validated using a DMI6000 inverted 
Leica TCS SP5 tandem scanning confocal microscope with a 63x/1.40NA oil immersion objective.  
405 diode, 488 Argon and 546 laser lines were applied to excite the samples using AOBS line 
switching to minimize crosstalk between fluorochrome.  Images and Z-stacks were produced with 
three cooled photomultiplier detectors and the LAS AF version 1.5.1.889 software suite.  
Statistical analysis: Data are expressed as the mean ± standard error of the mean 
(SEM).  Analyses were performed using a two-way ANOVA followed by Fisher’s LSD post-hoc 
analysis to identify significant effects.  Differences were considered significant at *p ≤ 0.05; **p ≤ 
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0.001.  A two tail unpaired t-test was performed to identify significant differences in the number of 
0X-6 immunolabeled cells between aged treated and aged control rats. 
Results  
Chronic administration of Ac-YVAD-CMK increases the number of BrdU-postive 
cells in the subgranule cell layer of the hippocampus. We previously demonstrated that 
infusion of the caspase-1 inhibitor Ac-YVAD-CMK significantly ameliorates impairment of 
hippocampal-dependent memory by decreasing caspase-1 and caspase-3 activity, as well as 
protein levels of IL-1β and TNFα in the aged rat hippocampus compared to controls (Gemma et 
al., 2005).The aim of the present study was to investigate whether the age-dependent increase in 
hippocampal IL-1β affects the age-related decrease in hippocampal neurogenesis.  The effects of 
a 28 -d infusion of Ac-YVAD-CMK (10 pmol) on cell differentiation in the SGZ in young (4 mo) and 
aged (20 mo) F344 rats was determined by analyzing 5’-bromo-deoxy-uridine (BrdU) staining 10 
dafter the last BrdU injection.  Figure 2 shows that BrdU - labeled cells in both young and aged 
rats were primarily located on the border of the granule cell layer.  Unbiased stereologic 
quantification of total BrdU -labeled cells in the SGZ revealed that the number of newborn cells 
generated over a period of 5 d was much higher in young than in aged rats.  The results were 
subjected to a 2 (age: young, aged) X 2 (treatment: saline, caspase-1 inhibitor) factorial ANOVA 
(Fig. 3).  There was a significant effect of age (F (1, 13) = 76.84, p < .001), but no significant 
effect of treatment (F (1, 13) = 1.13, p = .306).  Further, the age X treatment interaction was not 
statistically significant (F (1, 13) = 2.37, p = .148).  Although the interaction was not statistically 
significant, the means clearly indicate that the response of the aged animals was different from 
that of the young animals to caspase-1 inhibition.  The lack of interaction was likely due to the fact 
there was no treatment effect in the young animals and therefore the interaction itself was not that 
strong.  Despite the lack of a significant interaction, we compared the treatment effects for the 
young and aged animals separately, but corrected for multiple comparisons because the original 
interaction was not statistically significant.  The results confirmed that there was no treatment 
effect in the young animals (F (1, 6) = .06, P< = .822), but the effect in the aged group was 
statistically significant (F (1, 7) = 19.13, P = .003).  There was an increase of 53% in the number 
of BrdU - labeled cells in the SGZ of aged rats compared to aged controls.  This was a substantial 
increase in neurogenesis, however, it was only 39% of the neurogenesis observed in young 
control rats.   
Determination of neuronal and glial phenotypes of BrdU - labeled cells in the 
subgranule cell layer of the hippocampus. We then determined the phenotype of the newly 
born cells using the neural nuclear protein NeuN and immature neural marker TuJ1.  We found 
that there was no difference in the proportion of BrdU – labeled cells expressing neuronal or glial 
phenotype in the SGZ between aged treated and aged control rats (Fig. 4).  Our analysis 
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revealed that 54% of BrdU - labeled cells in the aged control animals expressed NeuN, while the 
percentage of BrdU/NeuN - positive cells in the aged treated rats increased to 73% (Tab. 1).  The 
immature neural marker TuJ1 was expressed in 43% of BrdU - labeled cells in aged treated rats 
and 38% of cells in aged control rats.  We then examined if there was a change in the glial 
phenotypes.  We found that very few BrdU-labeled cells were positive for glial fibrillary acidic 
protein (GFAP; 4% control rats and 3% treated rats).  Because BrdU is a marker of DNA 
synthesis, there is a possibility that BrdU labeled cells are undergoing apoptotic cell death; thus, 
to investigate this possibility, we double-labeled the BrdU cells with caspase-3.  We found that 
only 6.5% and 5% of BrdU positive cells expressed caspase-3 in the control and treated rats 
respectively.  When the percentage of each phenotype was summed, it revealed a number 
greater than 100%, indicating that cells express more than one phenotype.   
Ac-YVAD-CMK decrease microglia activation. Because IL-1β activates microglia and 
activated microglia produce IL-1β, we explored whether the Ac-YVAD-CMK-induced increase in 
neurogenesis was accompanied by changes in microglial activation.  Microglia were identified by 
OX-6 a marker for the major histocompatibility complex class II antigen expressed by activated 
microglia.  Stereological counting was performed on OX-6 - labeled cells expressed in the dentate 
gyrus.   The stereologic cell count of OX-6 - positive cells revealed that caspase-1 inhibition 
caused a significant decrease in the number of OX-6 - positive cells in the aged treated dentate 
gyrus compared to controls (Fig. 5; p<0.01).  Interestingly, as shown in Figure 5B and 5C, a clear 
morphological difference in the OX-6 positive cells phenotype was observed between treated and 
non-treated animals.  In the non-treated animals microglia were characterized by highly ramified 
branching, indicating an activated state.  In the treated animals, microglia were characterized by 
long thin branches which indicate a more quiescent and resting state.  We were unable to detect 
enough OX-6 - positive cells in the hippocampus of young animals to perform a stereologic study.     
Discussion 
The present study explored whether the age-related increase in IL-1β contributes to the 
decrease in hippocampal neurogenesis associated with aging.  To examine this hypothesis, we 
used the irreversible caspase-1 inhibitor Ac-YVAD-CMK to block caspase-1 activity, which is 
known to be responsible for the production of the active mature form of IL-1β.  Consistent with the 
results of previous studies (Seki and Arai, 1995; Kuhn et al., 1996; Gould et al., 1998; 
Lichtenwalner et al., 2001; Bizon and Gallagher, 2003), we show that neurogenesis is 
dramatically reduced in aged animals.  In addition, we provide new evidence that chronic 
inhibition of caspase-1 activity increases the number of newborn cells in aged SGZ.  The 
percentage of the newly generated cells in the aged treated SGZ that differentiated into neural 
phenotypes, such as NeuN and TuJ1, however, remains similar to that observed in aged control 
animals.  This finding is in agreement with previous data showing that newly born cells in the 
aging dentate gyrus have a normal neuronal fate (Rao et al., 2006; Hattiangady and Shetty, 
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2008). Whether the increase in neurogenesis observed in the present study is due to an increase 
in cell proliferation or to protection and survival of the newly generated neurons cannot be 
explained by the present data.  Future studies looking at cell proliferation will help us to clarify this 
point.  Consistent with the detrimental role of inflammation on adult neurogenesis, Monje et al. 
(2003) reported that systemic administration of LPS in adult female rats inhibits hippocampal cell 
proliferation and this effect is completely blocked by the administration of a non-steroidal anti-
inflammatory drug.   
Upregulation of IL-1β and activation of microglia occur during normal aging and 
accompany many neurodegenerative diseases.  Concomitant with an increase in neurogenesis in 
aged treated rats, we observed a decrease in the number of activated microglia in the dentate 
gyrus.  A negative correlation between the degree of inflammation, indicated by the activation of 
microglia, and the number of newborn neurons was previously reported (Ekdahl et al., 2003; 
Monje et al., 2003). Thus, a decrease in microglial activation could also account for the 
restorative effect of caspase-1 inhibition on neurogenesis.  We observed a dramatic increase in 
the number of BrdU - labeled cell in the SGZ of aged treated rats compared to controls.  Even 
with this substantial increase, however, neurogenesis remained substantially lower (39%) than in 
young control rats.  This finding raises the question of whether neurogenesis is functionally 
important.  Interesting, the same dose of Ac-YVAD -CMK completely reverses the impaired 
cognition associated with aging (Gemma et al., 2005). Recently Rao et al (2006) demonstrated 
that the largest decrease in hippocampal neurogenesis occurs between 7.5 months and 12 
months of age, which corresponds to the period of adult-to-middle age, and there is a small 
decline from 12 to 24 months of age (Rao et al., 2006).  The authors suggest that there may be a 
threshold of minimal levels of neurogenesis that occurs in the adult brain below which declines in 
neurogenesis become detrimental, such as that observed at 24 months of age. If this hypothesis 
is correct the increase in neurogenesis observed in this report, although not back to that observed 
in very young animals, may be sufficient to cross above the threshold of minimal neurogenesis 
allowing for proper function of the adult brain.  In light of the results presented in this study, we 
postulate that the increase in newborn neurons induced by caspase-1 inhibition might stimulate 
endogenous mechanisms responsible for behavioral improvement. 
Multiple mechanisms might underlie the effect of caspase-1 activity on hippocampal 
neurogenesis in the aged brain.  In a previous report, we have shown that the administration of 
Ac-YVAD-CMK at the same dose used in the present study induced a 70% decrease of caspase-
1 activity and a 50% reduction of IL-1β protein in the hippocampus of aged rats (Gemma et al., 
2005). One possibility is that the increased number of newborn neurons observed here is due to 
the inhibition of IL-1β. The effect of IL-1β most likely depends on several factors.  For example, 
IL-1β activation triggers a cascade of molecular events that culminates in the alteration of other 
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proinflammatory cytokines, activation of prostaglandins, increases in glucocorticoids, and 
activation of apoptosis.  All these factors have been shown to decrease neurogenesis.  Thus, we 
cannot rule out the possibility that more than one mechanism is responsible for the beneficial 
effects of caspase-1 inhibition on neurogenesis.   
Caspase-1 is involved in the activation of both apoptosis and inflammation.  One 
important issue is whether the neuroprotective effects of caspase-1 inhibition on neurogenesis 
proceed exclusively via a cytokine-dependent pathway or whether its involvement in apoptosis is 
more critical.  We previously demonstrated that the inhibition of caspase-1 decreases 
hippocampal IL-1β levels and caspase-3 activity (Gemma et al., 2005). Whether the decrease in 
caspase-3 activity is a downstream effect of IL-1β inhibition or whether caspase-1 directly 
regulates caspase-3 activity cannot be determined in the present experiments.  Thus, the 
possibility that the neuroprotective effects of caspase-1 inhibition are a net consequence of a 
decrease in apoptosis cannot be ruled out.  However, the observation that caspase-1 knockout 
mice develop normally, with no apparent physiologic or morphologic aberrations, however, 
suggests that caspase-1 has no major role in programmed cell death during development.  
Although the results presented here show a clear effect of the caspase-1 inhibitor Ac-YVAD-CMK 
on hippocampal neurogenesis, it is important to point out that in the present study we did not 
measure the hippocampal activity of caspase-1 or the hippocampal protein levels of IL-1β after 
the administration of Ac-YVAD-CMK; thus, we can only assume that the administration of Ac-
YVAD-CMK led to a decrease in the caspase-1 activity which led to a decrease in IL-1β protein 
levels.  Thus, additional effects of Ac-YVAD-CMK in the brain may be responsible for the increase 
in hippocampal neurogenesis.  Indeed, it has been shown Ac-YVAD-CM can exert 
neuroprotective effects without affecting caspase-1 activity and IL-1β levels.  For example, the 
administration of Ac-YVAD-CMK counteract the gp-120-induced cytosolic cytochrome c elevation 
without affecting IL-1β levels (Corasaniti et al., 2005). Furthermore, Ac-YVAD-CMK has been 
shown to protect against oxygen and glucose deprivation-induced cell death in organotypic 
cultures of rat hippocampal slices independently from IL-1β inhibition (Ray et al., 2000). In 
conclusion, the findings in the present study demonstrated that the chronic intracerebroventricular 
administration of Ac-YVAD-CMK reverses the age-dependent decrease in hippocampal 
neurogenesis.  Further studies need to be conducted in order to investigate in more detail the 
molecular and cellular mechanism underlying the effect of Ac-YVAD-CMK on hippocampal 
neurogenesis in the age rats. 
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Table 1: To calculate the percentage of each phenotype with respect to the number of 
BrdU-labeled cells, the total number of BrdU - labeled cells and their respective phenotypes were 
scored in six or more sections of a one-in six series were scored.  The percentages were then 
expressed as an average of 4 to 6 animals. 
* Expressed as percentage of BrdU 
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Figure 2.  Inflammation decreases basal hippocampal neurogenesis. 
Immunohistochemical staining for BrdU - positive cells (20X) in the dentate gyrus after 28 d 
intracerebroventricular infusion of vehicle or Ac-YVAD-CMK in young control rats and aged rats.  
A. Young control rats; B. Aged control rats; C. Aged treated rats.  BrdU was injected 
intraperitoneally once a day for 5 consecutive days, and the rats were killed 10 d after the last 
injection of BrdU.  Note the presence of BrdU - immunoreactive nuclei located in the subgranular 
zone.  The number of BrdU-positive cells was dramatically lower in aged rats.
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Figure 3. Inhibition of caspase-1 attenuates the decrease in hippocampal 
neurogenesis associated with aging.  Stereologic quantification using an optical fractionator of 
BrdU-positive cells in young and aged rats following 28 d intracerebroventricular infusion of 
vehicle or Ac-YVAD-CMK.  The results were subjected to a 2 (age: young, old) X 2 (treatment: 
saline, caspase-1 inhibitor) factorial ANOVA.  The results indicate a significant effect of age (F (1, 
13) = 76.84, p < .001), but no significant effect of treatment (F (1, 13) = 1.13, p = .306).  Further, 
the age X treatment interaction was not statistically significant (F (1, 13) = 2.37, p = .148).  
Multiple comparison of Ac-YVAD-CMK effect for the young and aged rats revealed that there was 
no treatment effect in the young animals (F (1, 6) = .06, p = .822), but the effect in the old group 
was statistically significant (F (1, 7) = 19.13, p = .003).   
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Figure 4.  Representative confocal micrograph of BrdU-labeled newborn cells 
(BrdU, red) and their respective phenotypes (green) in the subgranular zone. 
A, B and C.  Overview of GFAP, NeuN and TuJ1 expression in the SGZ.  D and E. Single 
confonfocal plane of the same cell, showing co-localization of NeuN+ (green), BrdU+ (red) and 
BrdU+/NeuN+ (orange) cells and TUJ1+ (green), BrdU+ (red) and BrdU+/TuJ1+ (orange), in the 
SGZ of Ac-YVAD-CMK treated rats. Newly formed double-labeled neurons are visualized by 
using confocal microscopy in an orthogonal projection composed of 25 optical z-planes (0.5mm 
thick).  
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Figure 5.  Inhibition of caspase-1 significantly reduced microglia activation. A  
Stereologic quantification using an optical fractionator of the number of OX-6 - positive cells in the 
dentate gyrus of aged control and aged AC-YDAV-CMK treated rats. B and C are representative 
photomicrograph of OX-6 positive staining (10X) in the dentate gyrus of aged control rats (B) and 
AC-YVAD-CMK treated rats (C).  Note the morphological difference of OX-6 positive cells 
between treated and non treated animals. 
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Abstract 
Neurogenesis continues to occur throughout life but dramatically decreases with 
increasing age. This decrease is mostly related to a decline in proliferative activity as a result of 
an impoverishment of the microenvironment of the aged brain, including a reduction in trophic 
factors and increased inflammation. We determined that human umbilical cord blood 
mononuclear cells (UCBMC) given peripherally, by an intravenous injection, could rejuvenate the 
proliferative activity of the aged neural stem/progenitor cells. This increase in proliferation lasted 
for at least 15 days after the delivery of the UCBMC. Along with the increase in proliferation 
following UCBMC treatment, an increase in neurogenesis was also found in the aged animals. 
The increase in neurogenesis as a result of UCBMC treatment seemed to be due to a decrease 
in inflammation, as a decrease in the number of activated microglia was found and this decrease 
correlated with the increase in neurogenesis. The results demonstrate that a single intravenous 
injection of UCBMC in aged rats can significantly improve the microenvironment of the aged 
hippocampus and rejuvenate the aged neural stem/progenitor cells. Our results raise the 
possibility of a peripherally administered cell therapy as an effective approach to improve the 
microenvironment of the aged brain.  
Introduction 
Aging is accompanied by a process of cellular senescence that occurs throughout the 
body, resulting in a decrease in the regenerative potential of the stem cell pools (Collado et al., 
2007). In the brain there are two stem cell pools, one residing in the subventricular zone (SVZ), 
and the other in the subgranular zone (SGZ) of the dentate gyrus of the hippocampus. As in other 
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stem cell pools such as the hemapoietic pool in the bone marrow or the satellite stem cells in the 
muscle, the stem cells in the brain lose there capacity to generate new cells with age (Kuhn et al., 
1996; Cameron and McKay, 1999; Kronenberg et al., 2006b). In the brain it appears that the 
decrease in neurogenesis is a result of a decrease in proliferation of the stem cells and not due to 
a loss of the cells (Hattiangady and Shetty, 2006). In the muscle it has been shown that the stem 
cells can be rejuvenated by exposure of the cells to the systemic environment of a young animal 
through parabiosis (Conboy et al., 2005). Even though it has been known since the 1960s that a 
cellular senescence occurs with age (Hayflick and Moorhead, 1961), it is less clear if this cellular 
senescence leads to an aging phenotype, particularly to the age related cognitive decline.  
However, it is clear that the process of cellular senescence that occurs with age is an 
important mechanism to protect against cancer. There are a number of tumor-supressor genes, 
including p53 and p16ink4A , which respond to cellular stressors to induce senescence (Campisi, 
2005). It has recently been shown that knocking out p16ink4A can restore the proliferative potential 
of the aged neural stem cells (Molofsky et al., 2006), but the animals have decreased longevity 
due to tumor formation (Beausejour and Campisi, 2006). This demonstrates the important 
balance that oncogenes play in protecting organisms from cancer, but with the negative 
consequence of inducing an aging state of cellular senescence. An effective target to lessen the 
amount of senescence might be the cellular stressors that accumulate with age which include 
telomere shorting (Collado et al., 2007), oxidative stress (Harman, 1956; Ames and Shigenaga, 
1992; Ames et al., 1993), inflammation (Blalock et al., 2003), increased corticosteroid levels 
(Sapolsky, 1992), and a decrease in a number of trophic factors including brain-derived 
neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), Insulin-like Growth 
Factor-1 (IGF-1) and fibroblast growth factor 2 (FGF-2) (Hattiangady et al., 2005; Shetty et al., 
2005).  
A potent cellular stressor that is increased with age is inflammation. Recently, our 
laboratory has shown that reducing neuroinflammation in aged rats by blocking the conversion of 
pro-IL-1β to IL-1β through inhibition of the converting enzyme caspase-1 rescued some of the 
age-related decrease in neurogenesis (Gemma et al., 2007a) and resulted in an improvement in 
cognitive function (Gemma et al., 2005). We believed that human umbilical cord blood 
mononuclear cells (UCBMC) may have a similar potential to restore some of the loss in capacity 
of the neural stem/progenitor cells ability to proliferate and differentiate into neurons. 
In an animal model of stroke, UCBMC administered intravenously have reduced infarct 
volume and improved functional recovery on behavioral measures (Vendrame et al., 2004). The 
effects of UCBMC have been attributed to changes in the microenvironment of the brain, through 
the release of trophic factors or by reducing inflammation, and not by a direct replacement of cells 
(Borlongan et al., 2004; Vendrame et al., 2005; Newman et al., 2006). UCBMC contains a 
number of cell types including B-Cells and T-Cells, as well as, mesenchymal and endothelial 
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progenitor cells. UCBMC is also a rich source of CD34+ hematopoietic stem cells (Bender et al., 
1991; Ho et al., 1996; Wu et al., 1999). It was recently demonstrated that a systemic injection of 
UCBMC cells could suppress inflammation in the brain following stroke. Moreover, the effects of 
UCBMC cells seemed to shift the cytokine expression from a Th1 response to a Th2 response 
(Vendrame et al., 2004; Vendrame et al., 2005; Vendrame et al., 2006a). In addition to the 
immune modulatory effects, UCBMC cells also produce a number of trophic factors including, but 
not limited to, VEGF, nerve growth factor, and cytokine colony stimulating factor-1, 
thrombopoietin, and IL11 (Suen et al., 1994; Taguchi et al., 2004; Vendrame et al., 2004). 
The goal of the present study was to determine if UCBMC could stimulate the 
endogenous stem/progenitor cells to regenerate new cells. To this end, young and aged rats 
were intravenously administered a single dose of UCBMC to determine if UCBMC could increase 
proliferation of the neural stem/progenitor cells as well as to determine if there would be an effect 
on neurogenesis in the aged rats. This study provides insight into how the aged stem cell niche 
could be rejuvenated. Furthermore, as the UCBMC are administered minimally invasively this 
study raises the possibility of a clinically applicable therapeutic for the aged brain. 
Material and Methods  
Cell preparation: Cryopreserved human umbilical cord blood mononuclear cells 
(UCBMCs) were obtained from Saneron CCEL Therapeutics, Inc. (Tampa, FL, USA). 
Cryopreserved Human peripheral blood cells (PBMC) (mononuclear fraction) were obtained from 
AllCells, LLC (Emeryville, CA, USA). Just prior to intravenous (i.v.) injection, the UCBMC or 
PBMC were thawed into media (Hanks' balanced salt solution, HBSS, Gibco) at 37°C, washed, 
and the number of viable cells was determined using the trypan blue exclusion method 
(Vendrame et al., 2005). Cell viability ranged from 85 to 88%. Cell concentration was adjusted to 
106 viable cells/500μl. Rats were then anesthetized with 3% isofluorane and randomly chosen to 
receive a single i.v. injection via the penile vein of  UCBMC at a dose 106 cells shown most 
effective in a stroke model (Newman et al., 2006), 106 PBMC, or media for both the aged and 
young rats. 
Animals: All experiments were conducted in accordance with the National Institute of 
Health Guide and Use of Laboratory Animals, and were approved by the Institutional Animal Care 
and Use committee of the University of South Florida, College of Medicine. Male Fisher 344 
(F344) rats (NIA contract colony, Harlan Sprague Dawley, Indianapolis, IN), were pair-housed in 
environmentally controlled conditions (12:12h light:dark cycle at 21±1°C) and provided food and 
water ad lib. Two age groups of animals young (3 months old) and aged (20 months old) were 
used in this study.  The mean life span of the F344 rats is approximately 29 months with a 
maximal life span of 36 months (Coleman et al., 1977).  
Rats were then divided in three groups.  Group 1 received 50 mg/kg of bromodeoxyuridine (5-
bromo-2-deoxyuridine, BrdU; Sigma, St. Louis, MO, USA), intraperitoneal (i.p.) twice a day 
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beginning 24 hours the injection of UCBMC, and were sacrificed the subsequent day. Rats in 
group 2 received BrdU (50 mg/kg, i.p.) twice a day, beginning fourteen days after the 
administration of UCBMC and were sacrificed on the following day.  Rats in Group 3 received 
BrdU (50 mg/kg, i.p.) for five consecutive days, beginning the day after the administration of 
UCBMC and were the sacrificed day fifteen. 
Tissue collection and processing: The rats were anesthetized with pentobarbital (50 
mg/kg, i.p.). Blood was collected by cardiac puncture and smears were made of the blood to look 
for the presence of the transplanted cells. The rats were transcardiac perfusion with phosphate-
buffered (PB), followed by 4% paraformaldehyde in PB. The brains were postfixed in 4% 
paraformaldehyde for 12 h, after which they were transferred into 30% sucrose in phosphate-
buffered saline (PBS) for at least 16 h, and stored at 4°C. Exhaustive caudal sections of the left 
hemisphere were made, at 40μm using a Microm cryostat (Richard-Allan Scientific, Kalamazoo 
Michigan) and stored in cryoprotectant at 4°C.   
BrdU Immunohistochemistry: All immunohistochemical staining was conducted on 
free-floating sections for every sixth section for the entire hippocampus beginning with a random 
start and including sections before and after the hippocampus to ensure that the entire structure 
was sampled; with one exception, in the aged animals from group 3 a one in three series was 
stained to allow for sampling of an adequate number of BrdU+ cells. For BrdU staining, sections 
were pretreated with 50% formamide/2X SSC (0.3 M NaCl, 0.03M sodium citrate) at 65°C for 2 
hours, rinsed in 2X SSC, incubated in 2N HCL for 30 minutes at 37°C, washed with borate buffer 
(pH 8.5), then PBS. This was followed by quenching endogenous peroxidase activity in 0.3% 
H2O2 solution in 30% methanol; then one hour in blocking solution (0.1M PBS supplemented with 
3% normal horse serum and 0.25% Triton X-100: PBS-TS); followed by incubation overnight with 
mouse-anti-rat-BrdU (1:100; Roche) in PBS-TS. The following day the sections were washed and 
then incubated for one hour in a biotinylated secondary antibody (1:200; Vector Laboratories, 
Burlingame, CA) in PBS-TS; then washed before one hour incubation in avidin-biotin substrate 
(ABC kit, Vector Laboratories, Burlingame, CA); and then washed before 10 minutes incubation in 
DAB solution (Vector Laboratories, Burlingame, CA). Sections were then mounted onto glass 
slides and coverslipped with mounting medium.  
Doublecortin and OX-6 Immunohistochemistry: Doublecortin (DCX) is a marker of 
migrating neurons that is expressed for approximately three weeks after the cell is born and has 
been shown to be a reliable indicator of neurogenesis (Rao and Shetty, 2004; Couillard-Despres 
et al., 2005).  For DCX immunohistochemistry a polyclonal goat antibody raised against human 
DCX (1:200; SC-8066, Santa Cruz biotechnology, Santa Cruz, CA, USA) was used following a 
similar protocol to BrdU except the antigen retrieval steps were omitted and Goat serum (Vector 
Laboratories, Burlingame, CA) was used instead of horse serum. For OX-6 
immunohistochemistry a monoclonal antibody directed against the rat major histocompatibility II 
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(MHCII) (RT1B, Becton, Dickinson Pharmingen, San Diego, CA, USA) was used at a 
concentration of 1:750 in place of the other primary antibodies all other steps were the same.  
Immunofluorescence: Tissues were pretreated with 2N HCL for 2 hours at room 
temperature, washed, and incubated in blocking solution (0.1M PBS containing 10% goat serum 
and 0.3% Triton X-100) for 1 hour at room temperature. Tissues were then incubated in rat anti-
BrdU (1:400; Accurate Chemical, Westbury, NY) and additional primary antibodies [anti-GFAP 
(1:500; Dako, Carpinteria, CA), mouse anti-NeuN (1:100; Chemicon, Temecula, CA), mouse anti-
TUJ1 (1:800; Convance, Berkeley, CA)], overnight at 4°C. Tissues were then rinsed 3 times in 
PBS and the appropriate secondary antibody conjugated to an Alexafluor probe (Molecular 
Probes, Eugene, OR) was applied for 2 hour. Following 6 washes in PBS, tissues were mounted 
on slides and coverslipped using Vectashield (Vector Labs, Burlingame, CA). 
Human Nuclei immunofluorescence: To detect for the presence of the transplanted 
cells, blood smears and tissue sections were stained with a mouse monoclonal antibody that 
recognizes Human Nuclei antigen (HuNu) (MAB 1281; 1:50; Chemicon, Temecula, CA ), and 
does not react with rat nuclei. Prior to incubation overnight at 4°C in the HuNu antibody, the 
samples were washed in PBS and incubated in blocking solution (0.1M PBS containing 10% goat 
serum and 0.3% Triton X-100) for 1 hour at room temperature. The HuNu antibody was visualized 
by secondary antibody conjugated to an Alexafluor probe (Molecular Probes, Eugene, OR). 
Quantification and imaging: To determine cell numbers the optical fractionator method 
of unbiased stereological cell counting techniques (West et al., 1991) was used with a Nikon 
Eclipse 600 microscope and quantified using Stereo Investigator software (MicroBrightField, 
Colchester, VT). For the proliferation study, because of the low number of BrdU+ cell in the aged 
animals the virtual grid and counting frame were both 125μm x 125μm in order to count all the 
cells that were present in the section. For all other counts sampling was optimized to count at 
least 200 cells per animal with error coefficients less than 0.07. Outlines of the anatomical 
structures were done using a 10x/0.45 objective and cell quantification was conducted using a 
60x/1.40 objective. OX-6+ cells were counted in the entire dentate gyrus including the subgranular 
zone (SGZ: defined as a two cell diameter band on both sides of the granular cell layer (GCL)). 
All other cell counts were done in the SGZ/GCL. The phenotype of the BrdU+ cells were analyzed 
using an inverted Zeiss LSM 510 confocal microscope with a 40x/1.30NA oil immersion objective. 
Argon and HeNe laser lines in conjunction with 488 and 555 band pass filters were applied to 
excite the samples using line switching to minimize crosstalk between fluorochromes.  Images 
and Z-stacks were produced with dual photomultiplier detectors and the LSM 5 version 3,2,0,115 
software suite, and  optical Z stacks where created at 2μm intervals throughout the 40μm of the 
sections with a guard region of 2μm excluded from top and bottom of the Z stack. The Z stacks 
were rotated in all planes to verify double labeling.   
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Statistical analyses: Data are presented as mean cell number ± SEM. Statistical 
analysis was performed using an unpaired, two-side t-test, or a one-way ANOVA followed by a 
Tukeys post-hoc test. p<0.05 was considered to be significant.  
Results 
Human umbilical cord blood mononuclear cells (UCBMC) stimulate proliferation of 
the senescent hippocampal neural stem cell. In the first of a series of experiments we wanted 
to determine if UCBMC given intravenously could stimulate the proliferation of the endogenous 
stem/progenitor cells in the hippocampus. We chose to study proliferation as a slowing of the cell 
cycle and a decrease in proliferation seems to be most affected with age when compared to the 
ability of the cells to survive and differentiate into neurons which appears to occur at relatively the 
same rate in young animals (Rao et al., 2005). The effect of a single intravenous injection of 
UCBMC on cell proliferation in the granule cell layer in young (3-months old ) or aged (20-months 
old) F344 rats was determined by analyzing BrdU staining 24 hours after the BrdU injections (48 
hours following UCBMC injection). Using the optical fractionator method of design based 
stereology (West et al., 1991), we found that in the aged animals there was a significant increase 
(t(9)= 4.256; p < 0.005) in the number of BrdU+ cells in the UCBMC group (2504 ± 227.3 n=5) 
compared to the animals that received media alone (1549 ± 82.07 n=6) (Figure 6A). In young 
animals there was no significant effect of the UCBMC treatment (data not shown). To determine if 
there might be a prolonged effect on proliferation in the aged F344 rats BrdU injections were 
given 14 days after the UCBMC treatment. Figure (6E) shows the effect of a single intravenous 
injection of UCBMC on the number of cells that incorporated BrdU on day 14. Stereological 
analysis revealed that in the aged UCBMC-treated rats there was a significant increase in the 
number of BrdU+ cells (t(12)= 3.468; p < 0.01) (2357 ± 149.4 n=6) compared to the media-treated 
group (1548 ± 176.9 n=4). 
Neurogenesis is stimulated in the aged hippocampus following UCBMC treatment. 
To determine if UCBMC would also stimulate neurogenesis in the aged rats, doublecortin (DCX) 
immunostaining was examined. Counting the number of DCX+ cells in the SGZ/GCL, we found a 
significant increase (t(16)= 2.188; p < 0.05) in the number of DCX+ cells in the aged rats 15 days 
after a single i.v. injection of the UCBMC (2619 ± 212.6 n=9) compared to animals that received 
media alone (1843 ± 283.9 n=9) (Figure 7A). To confirm the results obtained by DCX, and to 
determine if there was any change in the ability of the proliferating cells to differentiate following a 
UCBMC treatment, we injected the animals with BrdU (50mg/kg) for five days beginning 24 hours 
after our i.v. treatment. Quantifying the number of BrdU+ cells in the SGZ/GCL using the optical 
fractionator method of design based stereology we found a similar increase in the number of 
BrdU+ cells in the aged UCBMC treated group as was found using the neurogenic marker DCX 
(Figure 7A-D).  In aged rats, there was a significant increase (F(2, 14) = 10.94, p < 0.005) in the 
number of BrdU+ cells generated over a period of five days following a single i.v. injection of 
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UCBMC (2772 ± 263.3 n=5) compared to the rats that received media alone (1498 ± 206.1 n=5); 
as determined by the Tukey’s Multiple Comparison Test (p<0.01). In this experiment, we also 
included a group that was injected with adult human peripheral blood mononuclear cells (PBMC) 
as a control for the effect of delivering cells. The PBMC group was determined to have 
significantly fewer BrdU+ cells (1712 ± 171.2 n=5) than the UCBMC treated group (p<0.01), but 
this was not significantly different from the group that received media alone (Figure 7E-H). As 
with the results of the proliferation study, young rats showed no significant effect of UCBMC 
treatment (data not shown). To determine if the treatment with UCBMC might alter the phenotype 
of the newborn cells, we double labeled with the antibodies to Tuj1, NeuN and GFAP. While 
exhaustive sampling was not conducted, 50 BrdU+ cells were analyzed from each rat (4 rats per 
group) using confocal microscopy for each marker and there did not appear to be any change in 
phenotype due to the treatment (Figure 7I-J). To confirm that the increase in neurogenesis was 
from the endogenous stem/progenitor cells, sections were stained for HuNu to look for the 
presence of the transplanted cells in the brain. Cells positive for the HuNu were found in the 
blood smears of the rats that were treated with UCBMC, but no HuNu immunoreactive cells were 
found in the hippocampus of the rats (data not shown).  
A decrease in microglia activation following UCBMC correlates with the increase in 
neurogenesis. Using the optical fractionator method of design based stereology, we counted the 
number of OX-6+ cells in the dentate gyrus 15 days after a single UCBMC injection; this was at 
the same time point that we observed an increase in DCX+ cells and BrdU+ cells. OX-6 is a 
marker for MHCII and presumably stains for microglia in an activated, proinflammatory state. In 
aged rats, we found that 15 days after the UCBMC treatment there was a significant decrease 
(t(12)= 2.699; p < 0.05) in the total number of activated OX-6+ microglia in the UCBMC group 
(678.7 ± 155.3 n=7) compared to the media control (1217 ± 128.0 n=8) (Figure 8A). The 
decrease in OX-6+ microglia negatively correlated with the number of DCX+ cells (Spearman 
r(15)= -- 0.6429; p<0.01) (Figure 3E).  
Morphologically the OX-6+ cells expressed two main phenotypes (see Figure 8F). Type 1 
microglia appear to be in a more quiescent state based on morphology Type 2 microglia were 
thought to represent a more activated state. The type 1 microglia make up the majority of the OX-
6+ cells in the dentate gyrus and were found to be significantly decreased (unpaired t(12)= 2.791; 
p < 0.05) in aged rats following UCBMC treatment (426.6 ± 117.0 n=7) compared to controls 
(842.4 ± 94.67 n=8) (Figure 8G). The type 2 microglia, while representing a smaller percentage of 
the total OX-6+ microglia, were significantly reduced (t(12)= 3.281; p < 0.01) to a greater extent by 
the UCBMC treatment (53.30 ± 13.27 n=7) compared to controls (212.9 ± 43.82 n=8) than the 
total microglia (Figure 8H). Fifteen days after the UCBMC treatment, there was a 4 fold change in 
the number of type 2 OX-6+ microglia, whereas there was only a 1.8 fold change in the total 
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number of OX-6+ microglia. It appears that the highly activated microglia are being reduced to a 
greater extent by the UCBMC treatment, although all OX-6+ microglia are affected.  
Discussion 
The present study explored whether human umbilical cord blood mononuclear cells 
(UCBMC) could improve the neurogenic niche of the aged brain and stimulate the endogenous 
stem/progenitor cells to generate new neurons. As determined by stereological analysis of both 
DCX and BrdU, a single peripherally administered injection of UCBMC appeared to stimulate 
neurogenesis. The finding that the administration of UCBMC also increased the number of 
proliferative cells generated within 24 hours following the treatment, suggests that the increase in 
neurogenesis observed in this study may be a consequence of an increase in proliferation rather 
than changes in differentiation or survival of newly generated cells. To support this hypothesis, it 
will be important to allow more time for the cells to fully mature and then determine if there is still 
no change in the phenotype of the BrdU+ cells. It will also be important to determine what effect 
UCBMC have on the survival of the BrdU+ cells. 
 In addition, it was determined that UCBMC were able to increase cell proliferation for at 
least fifteen days in the aged rats. This suggests that the UCBMC may have a beneficial effect on 
the microenvironment of the aged brain. In support of this hypothesis we show that coinciding 
with an increase in neurogenesis in the aged treated rats, there was a decrease in the number of 
activated microglia in the dentate gyrus. A negative correlation between the degree of 
inflammation as indicated by the activation of microglia and the number of newborn neurons has 
been previously described (Ekdahl et al., 2003). Consistent with previous studies showing that 
UCBMC have the potential to reduce neuroinflammation (Vendrame et al., 2004; Rao et al., 2005; 
Vendrame et al., 2005; Vendrame et al., 2006a) in the aged brain, we did find that neurogenesis 
correlated with the number of activated microglia, suggesting that UCBMC were stimulating 
neurogenesis by decreasing microglia activation. Although other possibilities cannot be excluded, 
since UCBMC could be having multiple effects including increasing trophic support as previously 
published (Suen et al., 1994; Taguchi et al., 2004; Vendrame et al., 2004). 
UCBMC have been shown to reduce neuroinflammation (Vendrame et al., 2004; Rao et 
al., 2005; Vendrame et al., 2005; Vendrame et al., 2006a) and, consistent with previous studies, 
we show here that the peripherally administered UCBMC do have anti-inflammatory properties. It 
appears that one of the factors that leads to the negative regulation of neural stem cells is 
inflammation (Ekdahl et al., 2003; Monje et al., 2003; Battista et al., 2006). A primary source of 
inflammation in the CNS is from the macrophages/microglia which can produce a wide array of 
cytotoxic factors, including proinflammatory cytokines such as tumor necrosis factor (TNF), IL-1, 
IL-6 and IL-12 (Gao et al., 2002; Mantovani et al., 2004). With age, microglia shift from a 
quiescent state into an active proinflammatory state. It is not clear if this change in activation state 
is in response to injury, infection, or debris or if it is due to dysregulated cytokine levels. Another 
 35
possibility recently proposed, is that microglia becoming senescent and this leads to them 
becoming dysfunctional (Schwartz et al., 2006b; Streit, 2006b). It has previously been 
demonstrated in models of induced inflammation through the use of LPS or radiation, a dramatic 
decrease in proliferation and neurogenesis occur, and when the inflammation is alleviated the 
replicative potential of the stem cells returns (Ekdahl et al., 2003; Monje et al., 2003). This effect 
is likely a protective mechanism so that the DNA is not exposed to the noxious inflammatory 
environment which could damage the replicating DNA. This correlation also imparts support to 
the hypothesis that UCBMC stimulate neurogenesis by decreasing inflammation, particularly the 
activation state of microglia. However, it does not rule out the possibility that UCBMC may be 
acting on multiple targets, with microglia only representing one part of the total mechanism.  
While UCBMC do seem to have an effect on microglia, it is not clear how this occurs. A 
number of studies have shown that T-cells appear to act on macrophages/microglia to cause 
them to adopt a phenotype that is ‘pro-repair’ (i.e. the macrophages/microglia: clear debris, buffer 
toxic compounds, and produce growth factors), without being pro-inflammatory (i.e. producing 
TNF-α, NO, or COX-2) and this effect can promote neurogenesis and be neuroprotective (Shaked 
et al., 2004; Butovsky et al., 2006c; Ziv et al., 2006a; Ziv et al., 2006b; Ziv et al., 2007). As T-cells 
are a major fraction of UCBMC, it is possible that the naïve T-cells in the UCBMC are able to 
induce a protective T-cell mediated response in the aged rats, since adult PBMC did not have an 
effect. Alternatively, the CD34+ stem cells in the UCBMC may be involved. Taguchi et al. 
(Taguchi et al., 2004) has shown that CD34+ stem cells can increase both angiogenesis and 
neurogenesis as part of the protective mechanism against stroke. From the results of the current 
study it can not be determined if the effects of the UCBMC are a result of direct action on the 
brain or though peripheral effect. However, the fact that we did not detect any immunoreactivity 
for human nuclei in the brains of the UCBMC-treated rats raises the possibility that the UCBMC 
may be acting through a peripheral mechanism. Moreover, the observation that the adult PBMC 
did not alter hippocampal neurogenesis ruled out the possibility of a non-specific effect due to an 
influx of cells, supporting our belief that the increase in neurogenesis, which occurred following 
treatment with UCBMC was not due to an influx of cells but was specific to UCBMC. 
The present study did not attempt to determine if decreasing senescence of the neural 
stem cells could reverse the cognitive decline with age. There is still much debate surrounding 
the role of neurogenesis in learning and memory (Gould et al., 1999a; Shors et al., 2001; Shors et 
al., 2002; Merrill et al., 2003; Leuner et al., 2006; Kee et al., 2007) and whether cellular 
senescence of the stem cell pool with age leads to an aging phenotype. While not a goal of the 
current study, it will be important to determine if the rejuvenation of the aged stem/progenitor cell 
pool can reverse the age-related cognitive decline.  
In summary, this study demonstrates that a single peripheral injection of UCBMC could 
stimulate the endogenous neural stem/progenitor cells to increase proliferation. We also 
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determined that the UCBMC were able to improve the microenvironment of the aged brain by 
reducing the number of activated microglia, and this reduction is correlated with an increase in 
neurogenesis. Further work will be important to determine the mechanism of action of UCBMC in 
the aged rats, including the possible role of the immune system in a T-cell mediated response, as 
well as the affects of angiogenesis via the CD34+ stem cells. It will also be important in future 
experiments to determine the duration that a single injection of UCBMC will elevated proliferation 
in aged rats. Not only do the results of this study provide novel insight into the state of the aged 
stem cell niche, the ability of the UCBMC to exert their effects while being administered minimally 
invasively may make translation to the clinical setting more likely. For this reason it will be 
important in future studies to determine the most efficacious dose and dosing regimen. 
Nevertheless, this is the first time that a systemic injection of hematopoietic cells has been shown 
to restore the regenerative potential of the aged brain, providing a novel insight into how the 
regenerative potential of the aged stem cell niches could be restored.  
Conclusions  
The results demonstrate that a single intravenous injection of UCBMC in aged rats can 
significantly improve the microenvironment of the aged hippocampus and rejuvenate the aged 
neural stem/progenitor cells. Our results raise the possibility of a peripherally administered cell 
therapy as an effective approach to improve the microenvironment of the aged brain. 
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Figure 6: Proliferation is increased in aged rats following UCBMC treatment. To 
determine if UCBMC could stimulate proliferation of the hippocampal neural progenitor/stem cells 
rats received two i.p. injections of BrdU (50 mg/kg) and were sacrifice the following day. (A) 
Quantification of the BrdU immunoreactive cell in the SGZ/GCL in aged rats 2 days after the 
UCBMC treatment showed that there was a significant (p<0.005) increase in the number of BrdU 
immunoreactive cells. (B,C) Photomicrographs of the dentate gyrus of a media-treated rat (B) and 
a UCBMC-treated rat (C) shows the BrdU staining in those animals sacrificed 2 days after the 
treatment. (D)The arrow in C points to a cluster of BrdU immunoreactive cells from the UCBMC-
treated rat shown in D at higher magnification. (E) To determine how long proliferation might 
remain elevated injections of BrdU (50 mg/kg) began 14 days after the treatment. Quantification 
of the BrdU immunoreactive cells determine that the UCBMC-treated group had significantly 
(p<0.01) more cells in the SGZ/GCL then the animals that received media alone. (F,G) BrdU 
staining of the media-treated (F) and the UCBMC-treated (G) animals in the dentate gyrus of the 
hippocampus 15 days after the treatment. (H) Arrow in G points to cells shown at higher 
magnification in H. (scale bar for B,C,F,G is 100µm; scale bar for D,H is 25µm)
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Figure 7: 15 days after a UCBMC treatment neurogenesis is increase in aged rats.  
To determine if UCBMC treatment could stimulate neurogenesis aged F344 rats were sacrificed 
and immunohistochemical stained for DCX and BrdU. (A) A significant increase (p<0.05) in the 
number of DCX+ cells, quantified in the SGZ/GCL, was found in the UCBMC treated rats. (B,C) 
Photomicrographs show the dentate gyrus demonstrating the DCX immunohistochemistry in the 
media-treated (B) and UCBMC-treated (C) rats. (D) A higher magnification photomicrograph of 
area indicated in C shows a number of DCX+ cells showing the different morphologies of the 
cells.  (E) The results obtained with DCX were confirmed by BrdU. BrdU was injected i.p. for five 
consecutive days after the single injection of UCBMC. 10 days after the last injection of BrdU the 
animals were sacrificed. Compare to both a media control as well as an human adult peripheral 
blood (PBMC) control the UCBMC treated animals had significantly more BrdU+ cells (p<0.01). 
(F,G,H) Photomicorgaphs of dentate gyrus shows BrdU immunohistochemistry in the media-
treated (F), PBMC-treated (G) and UCBMC-treated (H) rats. (I,J) Immunofluorescence was 
conducted to determine the phenotype of the BrdU+ cells. (I) An example of the cells double 
labeled with BrdU+/NeuN+  (I; shown in orthogonal projection) and BrdU+/TUJ1+ (J; shown using 
maximum projection). (scale bar for B,C,F,G,H is 100µm; scale bar for D is 25µm)
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Figure 8: The decrease in microglia activation correlates with neurogenesis. 15 
days after the UCBMC treatment a significant reduction (p<0.05) was found in the number of OX-
6+ cells in the dentate gyrus of the aged rats (A). (B,C) Photomicrographs are shown of the 
hippocampus of media-treated (C) and UCBMC-treated (C) rats. (D) A higher magnification 
photomicrograph of area indicated by arrow in B. (E) A significant negative correlation (p<0.01) 
was found between the number of OX-6+ cells and the amount of neurogenesis as determine by 
the number of DCX+ cells. (F) The OX-6+ were further characterized based on morphology. The 
cell on the left represents a typical ‘Type 1’ cell the cell on the right represents a typical ‘Type 2’ 
cell. Both ‘Type 1’ (p<0.05; G) and ‘Type 2’ (p<0.01; H) OX-6+ cells were significantly reduced in 
the aged animals following UCBMC treatment, but there was a greater reduction in ‘Type 2’ cells 
amounting to a four fold change. (scale bar for B,C is 200µm; scale bar for D is 25µm).
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Abstract 
 Cellular senescence occurs throughout the body during chronological aging of an 
organism. A portion of senescence is independent of primary alterations to the stem cells, and is 
dependent on the environment where the cells reside. While microglia have neuroprotective 
capacities, their chronic activation can promote neurotoxic inflammation, thereby contributing 
detrimental effects to the neural stem cell niche. The causes of age-related increases in microglial 
activation and neuroinflammation are currently not well understood. Neuronally-expressed 
fractalkine (FKN), acting via interaction with its receptor CX3CR1, can suppress excessive 
microglia activation. To address the role of this chemokine system in hippocampal neurogenesis, 
we examined the impact of interfering with FKN/CX3CR1 interactions in young and old rodents. 
Disruption of FKN/CX3CR1 signaling in young adult rodents decreased survival and proliferation 
of neural progenitor cells. These anti-neurogenic effects, resulting from loss of CX3CR1 function, 
were reversed by IL-1β antagonism. Aged rats had decreased levels of hippocampal FKN protein 
although interruption of CX3CR1 function in these animals did not affect neurogenesis. Moreover, 
delivery of exogenous FKN reversed the age-related decrease in hippocampal neurogenesis in 
aged rats but did not produce any effects in young animals. The results suggest that 
FKN/CX3CR1 signaling has a regulatory role in modulating hippocampal neurogenesis via 
mechanisms that involve indirect modification of the niche environment. As elevated 
neuroinflammation is associated with many age-related neurodegenerative diseases, enhancing 
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FKN/CX3CR1 interactions could provide an alternative therapeutic approach to slow 
neurodegeneration, while also minimizing non-specific immunosuppressive responses. 
Introduction  
Adult neurogenesis is a lifelong process, continuing even in elderly humans (Eriksson et 
al., 1998). However, studies in rodents have demonstrated a continual age-related decline in 
neurogenesis (Rao et al., 2006; Ben Abdallah et al., 2008). An extensive list of neurogenic 
regulators has been identified, many of which change as a result of aging (Drapeau and Nora 
Abrous, 2008) making a unified theory to account for the age-related decrease in neurogenesis 
unlikely. Yet, the potential importance of neurogenesis in some affective (Sahay and Hen, 2007) 
and cognitive behaviors (Drapeau and Nora Abrous, 2008), as well as endogenous tissue repair 
mechanisms, makes further investigation of neurogenic regulators warranted. Seminal studies 
demonstrated that microglia can be detrimental to neurogenesis (Ekdahl et al., 2003; Monje et al., 
2003). Proinflammatory cytokines, including IL-1β, IL-6, and TNF-α, have been shown to act 
directly on neural stem/progenitor cells (NPC)(Monje et al., 2003; Iosif et al., 2006; Koo and 
Duman, 2008). Microglia are pleiotropic, and can also support neurogenesis through the 
production of growth factors (Ziv and Schwartz, 2008). Therefore the involvement of microglia in 
the neurogenic niche is not clear, as microglia can both increase and decrease neurogenesis. 
Until recently, neurons were believed to be submissive to the effects of microglia; however, a 
number of neuronal signals were found that can regulate microglia activation (Biber et al., 2007), 
suggesting a neuron-microglia dialog. 
One neuronally derived signal that has been shown to be important in regulating the neurotoxic 
affects of microglia is the chemokine fractalkine (FKN; CX3CL1; neurotactin). In contrast to many 
other chemokines, FKN binds and activates a single receptor, CX3CR1.  Although there is some 
debate concerning the cell types expressing these two molecules, in vivo FKN is principally 
expressed on neurons while CX3CR1 is found on microglia (Harrison et al., 1998; Cardona et al., 
2006; Lauro et al., 2008). Previous reports establish that interactions between FKN and CX3CR1 
contribute to maintaining microglia in a resting phase, partially controlling their neurotoxicity.  FKN 
acts in vitro as an anti-inflammatory molecule by down-regulating IL-1β, TNFα, and IL-6 
production (Zujovic et al., 2000; Zujovic et al., 2001). FKN can also elicit neuroprotective effects 
on pure neuronal cultures (Meucci et al., 1998; Meucci et al., 2000; Tong et al., 2000). 
Moreover, mRNA and protein expression of CX3CR1 were found in isolated NPCs (Ji et al., 2004; 
Krathwohl and Kaiser, 2004). 
With age there is an increase in the number of activated microglia, which can suppress 
neurogenesis (Gemma et al., 2007b; Bachstetter et al., 2008). We hypothesized that, as a 
consequence of aging, FKN signaling becomes disregulated, which leads to increased microglial 
activation and decreased neurogenesis. Our findings demonstrate for the first time that 
FKN/CX3CR1 signaling is critical for the regulation of hippocampal neurogenesis. 
 42
Materials and Methods 
Animals. All experiments were conducted in accordance with the National Institute of 
Health Guide and Use of Laboratory Animals, and were approved by the Institutional Animal Care 
and Use committee of the University of South Florida, College of Medicine or the University of 
Florida as appropriate. CX3CR1-deficient (CX3CR1GFP/GFP) mice, backcrossed to the C57BL/6 
background for greater than 10 generations were obtained from JAX Laboratories (Bar Harbor, 
Maine). Colonies of the CX3CR1+/GFP and CX3CR1GFP/GFP mice were maintained at the University 
of Florida. Four-month-old male CX3CR1+/GFP and CX3CR1GFP/GFP littermates were used in the 
experiments. Male Fisher 344 (F344) rats (NIA contract colony, Harlan Sprague Dawley, 
Indianapolis, IN), were pair-housed in environmentally controlled conditions (12:12 h light:dark 
cycle at 21 ± 1°C) and provided food and water ad libitum. Three age groups of rats used in this 
study included: young (3 months old), middle aged (12 months old) and aged (22 months old). 
Animals were excluded from the study if they became jaundiced, had pituitary tumors, or 
developed post-surgery infections.  
Surgical procedure. For all surgical procedures, rats were anaesthetized with 
isofluorane. For intracerebroventricular infusion, a guide cannula was stereotaxically implanted in 
the left ventricle (AP, −1.0; ML, 1.6; DV, −3.5 mm) and connected to an osmotic minipump, which 
was inserted subcutaneously. For the first 7 days all rats received an osmotic minipump (Alzet 
Model, 2001: pumping rate, 1.0 µL/h; total volume, 200 µL) filled with sterile saline, to allow time 
for the rats to heal before drug treatment was started. After the first 7 days, a mid-scapular 
incision was made and the saline pump was switched for the treatment pump for either an 
additional 7 days (Alzet Model, 2001: pumping rate, 1.0 µL/h; total volume, 200 µL), 14 days 
(Alzet Model, 2002: pumping rate, 0.5 µL/h; total volume, 200 µL), or 28 days (Alzet Model, 2004: 
pumping rate, 0.25 µL/h; total volume, 200 µL). The treatments used in this study included: (1) 
rabbit-anti rat CX3CR1 blocking antibody (α-CX3CR1) (10µg per day; Torrey Pines Biolabs, San 
Diego, CA; Cat no. TP 501)(Milligan et al., 2004); (2) rabbit non-immune IgG (10µg per day; 
Sigma-Adrich; Cat no. I-5006); (3) recombinant rat FKN (aa 22-100) chemokine domain (30ng per 
day R & D systems, Inc.; Cat no. 568-FR/CF)(Milligan et al., 2004).  (4) r-metHu IL-1Ra (10µg per 
day; Amgen, Thousand Oaks CA). For controls, the proteins were heat-inactivated for 45 minutes 
in a water bath at 90oC. 
Thymidine analog labeling. Following the time line in Figure 2A animals received two 
intraperitoneal (i.p.) injections of one or more thymidine analogs with a 12 hour interval. 
Bromodeoxyuridine (BrdU) (5-bromo-2-deoxyuridine; Sigma, St. Louis, MO) was injected at dose 
of 50 mg/kg. Equimolar solutions, to be equivalent to the 50 mg/kg of BrdU, were prepared from 
chlorodeoxyuridine (CldU) (42.5 mg/kg; Sigma, St. Louis, MO) and iododeoxyuridine (IdU) (57.5 
mg/kg; MP Biomedicals) as previously described(Vega and Peterson, 2005). 
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Tissue collection and processing.  For immunohistochemistry studies animals were 
anaesthetized with pentobarbital (50 mg/kg, i.p.). The rats were transcardially perfused with 
phosphate-buffered saline (PBS), followed by 4% paraformaldehyde in phosphate-buffered. The 
brains were postfixed in 4% paraformaldehyde for 12 h, after which they were transferred into 
30% sucrose in PBS for at least 16 h at 4°C. Exhaustive sagittal sections of the left hemisphere 
were made at 40μm using a Microm cryostat (Richard-Allan Scientific, Kalamazoo Michigan) and 
stored in cryoprotectant at 4°C. For biochemical experiments, animals were deeply anaesthetized 
with isofluorane before decapitation. The brain was quickly removed and the brain regions were 
dissected. Hippocampal tissues were dissected from both hemispheres and collected separately. 
In animals that received treatment, only the hemisphere that received the treatment was used. In 
naïve animals, both hemispheres were included. Homogenization of tissues was performed using 
an ultrasonic cell disrupter, in a 1:10 weight/volume of ice cold cell lysis buffer (Cell Signaling 
Technology, Inc.; Danvers, MA; Cat no. 9803) and phenylmethylsulphonyl fluoride, 1 mm (Sigma, 
St. Louis, MO). Samples were centrifuged at 21,000 g at 4 °C for 15 min and supernatant was 
collected. Determination of total protein, using a Bradford protein assay (BIO-RAD Laboratories, 
Hercules, CA, USA) and an enzyme-linked immunosorbent assay (ELISA) were performed on the 
same day to avoid repetitive thawing of samples. The ELISA for both rat IL-1β (eBioscience, Inc.; 
San Diego, CA; cat no. 88-6010-22) and rat FKN (RayBiotech, Inc.; Norcross GA; Cat no. ELR-
Fractalkine-001C) were performed using a commercially available kit following the manufacturer's 
protocol. 
Real-Time RT-PCR. Dissected tissues stored at -80oC were used for RNA isolation using 
RNeasy mini-columns (Qiagen; Cat no. 74104) with on-column DNase treatment (Qiagen; Cat no. 
79254) according to the manufacturer’s protocol. RNA quantity was determined and normalized 
using Quant-iT™ RiboGreen® RNA Assay Kit (Invitrogen; Cat no. R11490). Integrity of the RNA 
was confirmed on an agarose gel assessing the 18s and 28s rRNA bands. Reverse transcription 
(RT) was done following the manufacturer’s protocol using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems; Cat no. 4368814).  A no template and a no RT control 
were conducted to control for contamination. qPCR reaction was performed using SYBR® Green 
PCR Master Mix (Applied Biosystems; Cat no. 4309155) following the manufacturer’s protocol, 
with the exception of variable annealing temperatures (55oC-65oC) as determined most optimal 
during primer validation. A melt curve beginning at 55oC and increasing by 0.5oC to 95oC every 
10 sec with fluorescence measured at each interval. A single peak in the melt curve was used to 
check for a single product. A standard curve that covers 3 logs was made of pooled cDNA from 
all the rats and used each plate to check the efficiency of the reaction as determined by the slope 
of the standard curve and to assess plate to plate variations.  All samples were run in triplicate. 
The primers that were used included; Rpl19 (NM_031103; sense: AATCGCCAATGCCAACTC; 
antisense: CCCTTCCTCTTCCCTATGC) as the reference gene, to normalize the expression of 
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FKN (NM_134455; sense: CGAGTTCTGCTGTCTACCAATCTG; antisense: 
GAAGTGGTGGACGCTTGAGTAG). Relative gene expression was calculated by the 2-∆∆CT 
method. 
Immunohistochemistry and Immunofluorescence. Except where specifically 
indicated, standard staining procedures were conducted on free-floating sections using every 
sixth section for the entire hippocampus beginning with a random start and including sections 
before and after the hippocampus to ensure that the entire structure was sampled. The standard 
staining procedures used began with 0.3% H2O2 solution in 30% methanol to block endogenous 
peroxidase activity (this step was omitted for immunofluorescence). Sections were blocked in 
10% normal serum from the species that secondary antibody was raised in, with the addition of 
0.1% Triton X-100. Sections were incubated, with primary antibody diluted in 3% normal serum 
with 0.1% Triton X-100, overnight at 4°C. For immunohistochemistry biotinylated secondary 
antibodies were diluted in 3% normal serum with 0.1% Triton X-100 and were incubated for 2 
hours at room temperature. For immunofluorescence appropriate secondary antibody conjugated 
to an Alexafluor probe (Molecular Probes, Eugene, OR) was applied for 2 hours. For 
immunohistochemistry, enzyme detection was done using avidin-biotin substrate (ABC kit, Vector 
Laboratories, Burlingame, CA) followed by color development in diaminobenzidine solution 
(Sigma, St. Louis, MO). For BrdU, sections were pretreated with 50% formamide/2× SSC (0.3 M 
NaCl, 0.03 M sodium citrate) at 65°C for 2 hours, rinsed in 2× SSC, incubated in 2N HCL for 30 
minutes at 37°C, and washed with borate buffer (pH 8.5). For IdU and CldU, sections were 
pretreated 2N HCL for 20 minutes at 37°C followed by a wash in borate buffer (pH 8.5). BrdU was 
detected using a mouse anti-BrdU (1:100; Roche; Indianapolis IN; Cat no.11 170 376 001, clone 
BMC 9318). CldU was detected with rat anti-BrdU (Accurate Chemicals, Westbury, NY Cat no 
OBT003 clone: BU1/75 (ICR1)). For IdU, mouse anti-BrdU (Becton Dickinson Bioscience, San 
Jose, CA; Cat no.347580, clone B44), was used at a dilution of 1:500. Doublecortin (DCX) is a 
marker of migrating neurons that is expressed for approximately three weeks after the cell is born 
and has been shown to be a reliable indicator of neurogenesis(Rao and Shetty, 2004; Couillard-
Despres et al., 2005). For DCX immuno-detection, incubation in primary antibody was done for 36 
hours at 4°C using a polyclonal goat antibody C-terminus of human DCX (1:200; SC-8066, Santa 
Cruz biotechnology, Santa Cruz, CA, USA). Ki67 is expressed in cells G1 through M phase of the 
cell cycle (Scholzen and Gerdes, 2000). For detection of Ki67, a rabbit anti-human Ki67 antibody 
(NCL-Ki67p; Novocastra Laboratories/Vision BioSystems, Newcastle upon Tyne, UK) was used 
at a dilution of 1:500. Mature neurons were stained with the marker NeuN (1:100; Chemicon, 
Temecula, CA). For OX-6 immuno detection a monoclonal antibody directed against the rat major 
histocompatibility II (MHCII) (RT1B, Becton, Dickinson Pharmingen, San Diego, CA, USA) was 
used at a concentration of 1:750. For microglia analysis in mice, two antibodies were used; 
mouse major histocompatibility II(I-A/I-E, Becton, Dickinson Pharmingen, San Diego, CA, USA; 
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Cat no. 556999 Clone: M5/114.15.2); and rat anti-mouse CD45 (AbD Serotec; Raleigh, NC; 
1:10,000; Clone: YW62.3; Cat no. MCA1031G). Detection of FKN was acomplished using a goat 
anti-rat polyclonal antibody that recognizes the chemokine domain of FKN at a concentration of 
1:100 (R&D Systems; Minneapolis, MN; Cat no. AF537).  
Quantification and imaging: To determine cell numbers, the optical fractionator method 
of unbiased stereological cell counting techniques (West et al., 1991) was used with a Nikon 
Eclipse 600 microscope and quantified using Stereo Investigator software (MicroBrightField, 
Colchester, VT). Due to the low number of BrdU+, CldU+, Idu+, and DCX+ cells in the aged 
animals, the virtual grid and counting frame were both 125μm x 125μm in order to count all the 
cells that were present in the section. For all other counts, sampling was optimized to count at 
least 200 cells per animal with error coefficients less than 0.07. Outlines of the anatomical 
structures were done using a 10x/0.45 objective and cell quantification was conducted using a 
60x/1.40 objective. An Olympus FluoView FV1000 confocal microscope was used for all 
Immunofluorescence photomicrographs, only linear adjustments (brightness and contrast) were 
made to the figures. When quantification of percentage of positive cells was determined, Z stacks 
were created at 1μm intervals throughout the 40μm of the sections with a guard region of 2μm 
excluded from top and bottom of the Z stack. The Z stacks were rotated in all planes to verify 
double labeling. 
Statistical analyses: Data are presented as mean±SEM. Statistical analysis was 
performed using an unpaired, two-side t-test, or a one-way ANOVA followed by unpaired t-test. 
Correlations were tested using a Pearson product-moment correlation coefficient.  A value of 
p<0.05 was considered to be significant. 
Results  
CX3CR1-deficient mice have decreased hippocampal NPC proliferation and 
neurogenesis. Previous studies suggest that CX3CR1 suppresses the neurotoxic effects of 
activated microglia (Cardona et al., 2006). However, in the absence of a neurotoxic insult, 
CX3CR1GFP/GFP mice lack any obvious phenotype, and appear to have normal brain development 
(Jung et al., 2000; Cook et al., 2001; Haskell et al., 2001). To date, no studies have investigated 
whether loss of CX3CR1 signaling results in changes in adult neurogenesis. To begin to address 
this issue, the number of DCX+ cells in the subgranular zone (SGZ) and granular cell layer (GCL) 
of the dentate gyrus in CX3CR1-expressing and deficient mice were quantified using the optical 
fractionator method of design based stereology. A significant decrease (t(9)=3.857; p=0.0062) in 
the number of DCX+ cells in the CX3CR1GFP/GFP mice was found as compared to the CX3CR1+/GFP 
mice (Fig. 10A). To determine if this decrease might be due to reduced proliferation, mice were 
injected twice (8 hours interval) with BrdU (50mg/kg) and the mice were euthanized on the 
following day. Quantification of the number of BrdU+ cells revealed a significant decrease 
(t(13)=2.513; p=0.026) in the number of BrdU+ cells in the CX3CR1GFP/GFP mice compared to the 
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CX3CR1+/GFP mice (Fig. 10B). Figure 1C shows that CX3CR1+ cells (green) were widely distributed 
in the dentate gyrus, with a typical appearance of ramified microglia. The CX3CR1+ cells in the 
SGZ had a morphological appearance of microglia and were located in close proximity to the 
NPC.  To determine whether neurons or astrocytes also expressed CX3CR1, sections from 
CX3CR1+/GFP mice and CX3CR1GFP/GFP mice were stained for GFAP (blue), BrdU (red), and NeuN 
(Magenta) (Fig. 10D) and for DCX (red) (Fig.10E-F). Colocalization of GFP with GFAP, NeuN, or 
DCX was not observed. Colocalization of BrdU and GFP was rarely seen, and most likely 
represented proliferating microglia and not expression of CX3CR1 on a NPC. Figure 10F-G 
shows CX3CR1+ cells adjacent to the DCX+ cells, with the CX3CR1+ cell processes interdigitating 
with the DCX+ cells (Fig. 10F) suggesting an important cell-to-cell regulation of the NPCs and the 
maturation and survival of the adult born neurons.  
Proliferation of NPCs is decreased by α-CX3CR1 treatment in young but not middle 
aged or old rats. To develop a pharmacological model of decreased FKN signaling, a blocking 
antibody to CX3CR1 was employed. This model allowed for transient loss of signaling as 
compared to the mouse model that, as a result of the permanent developmental loss of FKN 
signaling, might evoke compensatory mechanisms. To determine if blocking of CX3CR1 would 
cause a decreased NPC proliferation and neurogenesis as seen in the mouse model, we infused 
blocking antibody to CX3CR1 for 7 days via an osmotic minipump to the left lateral ventricle. 
Young adult rats (3 months old), middle aged rats (12 months old) and old aged rats (22 months 
old) were injected with BrdU on the 6th day of treatment. The animals were euthanized on the 
following day and sections of the hippocampus were evaluated for proliferation and short-term 
survival of the NPCs. Quantification of the number of BrdU+ cells in the SGZ showed a significant 
decrease (t(10)=4.688; p=0.0009) in the number of BrdU+ cells in the α-CX3CR1-treated rats 
compared to the non-immune IgG-treated animals (Fig.11A). To confirm the BrdU results, the 
number of Ki-67+ cells were quantified in the SGZ. A significant decrease (t(5)=3.596; p=0.0156) 
was found in the number of Ki-67+ cells in the α-CX3CR1-treated rats compared to the non-
immune IgG-treated animals (Fig.11B). This was also confirmed by quantification of the number 
of DCX+ cells. In the young adult rats a significant decrease in the number of DCX+ cells was 
found following treatment for 7 days with α-CX3CR1 (t(5)=2.629; p=0.0466)( Fig.11C). However no 
significant differences in the number of BrdU+ cells (Fig.11A), Ki-67+ cells (Fig.11B), or in the 
number of DCX+ cells (.Fig.11C), were found in the middle aged rats or old aged rats following 
treatment with the blocking antibody.   
FKN reversed the age-related decrease in neurogenesis, but had no effect in young 
or middle aged rats. To further investigate whether FKN/CX3CR1 signaling could modulate 
hippocampal neurogenesis, we treated the three different age groups of rats with 30ng/d of 
recombinant rat FKN. Following the same protocol used for the α-CX3CR1 study, FKN was 
continuously infused into the left ventricle by an osmotic minipump for 7 days. In the first 
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experiment, BrdU was injected 6 days following the beginning of the FKN treatment and the 
animals were euthanized on day 7 (Fig.12A). A significant increase (t(10)=2.639; p=0.0248; 
Fig.12B) in the number of BrdU+ cells in the aged rats treated with FKN was found as compared 
to the aged rats treated with heat-inactivated (HI)-FKN (Fig.12A). Quantification of the number of 
DCX+ cells in the aged rats after 7 days of FKN treatment indicated no significant difference 
between the two groups (Fig 12C). In the young adult and middle aged rats, FKN treatment did 
not produce any measurable changes in the number BrdU+ cells (Fig.13A), or in the number of 
DCX+ cells (Fig.13B). 
FKN treatment in aged rats mainly affects proliferation. To determine whether the 
disruption in FKN/CX3CR1 signaling induced changes in proliferation or survival of the newly born 
cells, we used a multiple thymidine analog approach. Both CldU and IdU were used to date new 
born cells at 2 different time points (see timeline Fig.12A). FKN was delivered via an osmotic 
minipump to the left lateral ventricle for 15 days. One day prior to the beginning of the treatment 
aged rats were injected with CldU (b.i.d.; 42.5 mg/kg; equimolar to BrdU). IdU was injected on 
day 6 (b.i.d.; 57.5 mg/kg; equimolar to BrdU), allowing an additional 7 days of treatment to 
measure the effect of treatment on the survival of IdU+ cells. Stereological quantification using an 
optical fractionator demonstrated no effect of FKN treatment in the number of CldU+ cells (Fig 
12D). In contrast, there was a significant increase (t(7)=3.831; p=0.0065; Fig.12E) in the number 
of IdU+ cells in the FKN-treated rats compared to the HI-FKN-treated rats. By comparing the 
number of BrdU+ cells in the first experiment to the number of IdU+ cells in the second experiment 
it is possible to determine if there were combined effects on survival and proliferation following 
treatment, or if these effects were limited to proliferation. In the aged rats, FKN increased the 
number of IdU+ cells. Comparison of the number of IdU+ cells to the number of BrdU+ cells, 
demonstrated that FKN treatment increased the survival by about 18%, but these changes were 
within 95% confidence interval (FKN 82.7%±16.45%; HI-FKN 64.7%±21.0%; mean±SD). The 
number of DCX+ cells was quantified to determine if the increased number of BrdU+ and IdU+ 
cells translated to an increase in DCX+ cells. After 14 days of treatment there was a significant 
increase (t(8)=2.945; p=0.0116; Fig.12H) in the number of DCX+ cells in the FKN group compared 
to the HI-FKN group. The increase in the number of IdU+ cells was found to significantly correlate 
with the number of DCX+ cells (Pearson r=0.933; p=0.0002; Fig 12I).  
Expression of FKN in the rat hippocampus. As we were able to reverse the age-
related decline in neurogenesis through the addition of recombinant FKN in the aged rats, we 
hypothesized that FKN might be altered with age. FKN levels in hippocampal tissue homogenates 
from young and aged rats were analyzed by ELISA. A significant decrease (t(16)=4.374; p=0.0005; 
Fig. 12A) in the level of FKN protein in the aged rats, compared to the young rats, was evident. 
However, mRNA levels of FKN were unaltered in the aged rats compared to the young rats 
(Fig.13B). We further investigated the protein localization of FKN in the dentate gyrus. Figure 13C 
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shows a photomicrograph of staining with DAPI (blue), FKN (green), and Tuj1 (red). While FKN 
was abundantly expressed on the cell bodies of presumable neurons in the GCL, FKN staining 
was not found on Tuj1+ cells. Moreover, photomicrographs of Ki-67 (red) and FKN (green) 
(Fig.13D,E) also demonstrated a lack of FKN expression on the proliferating cells. These data 
indicated that FKN is not expressed on immature neuronal cells; however, it is not clear exactly 
when FKN begins to be expressed on neurons. 
CX3CR1 blocking antibody increased IL-1β. To determine whether inhibition of 
CX3CR1 activity would lead to an increase in IL-1β protein levels, the CX3CR1 blocking antibody 
was infused in young rats for 28 days via an osmotic minipump. The 28 day time point was 
chosen to ensure that if there was a difference in IL-1β levels, the difference would be large 
enough to be easily detected by a standard ELISA. In Figure 15, we found that there was a 
significant effect in the amount of IL-1β following treatment for 28 days with the CX3CR1 blocking 
antibody (F(2,16)=16.89; p=0.0002). Compared to either the saline treated rats (t(11)=5.179; 
p=0.0003) or the non-immune IgG treated rats (t(7)=2.630; p=0.0339) the α-CX3CR1 treated rats 
had a significant elevation in IL-1β. The saline treated rats and the non-immune IgG treated rats 
were also significantly different from each other (t(10)=4.064; p=0.0023). Nevertheless, the data 
indicates that the pharmacological antagonism of CX3CR1 leads to increased production of IL-1β.  
IL-1β mediates the effects of α-CX3CR1 treatment. To determine if the anti-proliferative 
effects of the CX3CR1 blocking antibody were dependent on IL-1β, young rats were infused with 
IL-1 receptor antagonist (IL-1Ra) along with either the α-CX3CR1 or non-immune IgG, following 
the same 7 day protocol as described earlier. A One-Way ANOVA revealed a significant effect 
(F(3,17)=5.476; p=0.0081) in the number of BrdU+ cells (Fig.16A). To determine if the addition of IL-
1Ra could have an effect on NPC proliferation a comparison was made between the non-immune 
IgG groups that received an active IL-1Ra or a heat-inactivated (HI)-IL1Ra. No difference was 
found as a result of IL-1Ra, suggesting that antagonizing the effects of IL-1β in the control rats 
that received the non-immune IgG did not alter proliferation (IgG+IL-1Ra n=6; IgG+HI-IL1Ra 
n=4). The next comparison was made between the rats that received a heat-inactivated IL-1Ra 
along with the either the α-CX3CR1 or IgG. A significant decrease (t(7)=3.499; p=0.010) was found 
in the number of BrdU+ cells in the rats that received the α-CX3CR1 compared to the IgG group 
(α-CX3CR1+HI-IL-1Ra 4236±422.6 n=5). The results of this comparison replicate the findings in 
Fig.11B, demonstrating that without, an active IL-1Ra, treatment with α-CX3CR1 decreases 
proliferation of NPCs. A significant decrease was also found between the α-CX3CR1+HI-IL1Ra 
treated group and the non-immune IgG treated group that received the active IL-1Ra (t(9)=3.373; 
p=0.0082). Finally, to determine if the effects of the blocking antibody were mediated through IL-
1β we compared the rats that received the blocking antibody along with the active or inactive IL-
1Ra. In the α-CX3CR1 treated rats the addition of IL-1Ra was able to prevent the decrease in 
proliferation that occurred following treatment with the α-CX3CR1. There was a significant 
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difference in the number of BrdU+ cells (t(9)=4.220; p=0.0022); such that, the rats which received 
the blocking antibody with the inactive IL-1Ra had fewer cells than the rats that received the 
blocking antibody and an active IL-1Ra (α-CX3CR1+IL1Ra n=6; α-CX3CR1 HI-IL-1Ra n=5). The 
effects on proliferation following treatment with α-CX3CR1 appear to be mediated through IL-1β 
as the IL-1Ra was able to completely attenuate the decrease in proliferation following treatment 
with α-CX3CR1.  
To determine if IL-1β also mediated the decrease in neurogenesis found after treatment 
with α-CX3CR1, the number of DCX+ cells was quantified in the rats that received IL-1Ra along 
with α-CX3CR1 or non-immune IgG. After seven days of treatment a significant effect was found 
(F(3,15)=7.615; p=0.0025)(Fig.16B). To confirm the results from the two earlier experiments in the, 
CX3CR1GFP/GFP mice, and the initial experiment in rats, that demonstrated that loss of CX3CR1 
function caused a decrease in the number of DCX+ cells, a comparison was made between the 
rats that received the inactive IL-1Ra along with the α-CX3CR1 or non-immune IgG. A significant 
(t(7)=2.441; p=0.0447) reduction in the number of DCX+ cells was found in the rats that received 
the heat-inactivated IL-1Ra+ α-CX3CR1 group compared to the matching non-immune IgG group 
(HI-IL-1Ra+ α-CX3CR1 n=5; HI-IL-1Ra+IgG n=4). Rats that received the active IL-1Ra along with 
α-CX3CR1 showed the significant (t(8)=2.441; p=0.0358) decrease in the number of DCX+ cells 
induced by α-CX3CR1 was prevented by the addition of IL-1Ra (IL-1Ra+ α-CX3CR1 n=5). Rats 
that received the IL-1Ra with α-CX3CR1 were not significantly different than the IgG+HI-IL-1Ra 
group with respect to the number of DCX+ cells. The results demonstrate that the decrease in 
DCX+ cells following blocking antibody treatment was mediated through IL-1β.  
An unexpected finding was the physiological role of IL-1β in regulating neurogenesis. When the 
IL-Ra was given to the non-immune IgG group (IL-1Ra+IgG n=5) a significant reduction in the 
number of DCX+ cells was found compared to the non-immune IgG group that received the heat-
inactivated IL-1Ra (t(7)=6.573; p=0.0003). As there was not a significant decrease in proliferation 
in the IL-1Ra+IgG group the DCX data suggests that a physiological level of IL-1β is important for 
the survival of the DCX+ cells, a similar finding was previously reported (Spulber et al., 2008). The 
number of BrdU+ cells (green) that were also DCX+ (red) were quantified (Fig.16C), and no 
differences in the number of BrdU+/DCX+ cells was found between any of the groups in the 
percentage of double-labeled cells (81.75%±6.3%). 
CX3CR1 blocking antibody decreased survival of cells born prior to treatment. After 
seven days of α-CX3CR1 treatment, the number of DCX+ cells was significantly decreased in the 
young adult rats (Fig.16B). The decrease in DCX+ cells could be due to decreased proliferation, 
as measured at day six (Fig.16A). Alternatively, treatment with α-CX3CR1 could also decrease 
the survival of the immature neurons leading to a decrease in DCX+ cells. To determine if α-
CX3CR1 treatment affected survival of cells born prior to treatment, CldU was injected one day 
before the beginning of the 14 days of infusion of non-immune IgG or α-CX3CR1. Figure 2A 
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shows the different time points that were compared. Quantification of the number of CldU+ cells 
demonstrated a significant decrease (t(7)=3.566; p=0.0091; Fig. 16D) in the number of CldU+ cells. 
After 14 days of treatment, in the rats that received α-CX3CR1 fewer of the cells that were born 
the day before treatment began survived compared to the non-immune IgG group.  Figure 17 
shows CldU+/NeuN+ cells in the non-immune IgG group (Fig.17A) and α-CX3CR1 group 
(Fig.17B). 
The preceding experiments demonstrated that α-CX3CR1 treatment decreased 
proliferation of NPCs. To determine if α-CX3CR1 treatment could alter the survival of cells born 
during the treatment, IdU was injected on day six of a 14 day of treatment.  Day six was chosen 
so that a comparison could be made between the number of IdU+ cells and BrdU+ cells 
quantification from the earlier experiment (Fig.16A). In the α-CX3CR1 treatment group 
significantly (t(7)=2.506; p=0.0406; Fig. 16E) fewer IdU+ cells were found compared to the non-
immune IgG. To determine if there was an effect on survival or if the effects were limited to 
proliferation, the number of BrdU+ cells were compared to the number of IdU+ cells. Comparisons 
of BrdU+ to IdU+ revealed no difference between the treatment groups (α-CX3CR1 
49.6%±10.11%; IgG 50.7%±7.9%; mean ± SD), demonstrating that the decrease in the number of 
IdU+ cells was due to a decrease in proliferation and not survival. A decrease in survival was 
seen in the cells born prior to treatment. These results suggest, that following treatment with α-
CX3CR1, the niche environment becomes unfavorable for the survival of the new born cells, and 
the cells born before the change in environment die.  After the change in environment, there is a 
decrease in proliferation but not survival as the number of cells born is limited to what the 
environment can support. The changes in the niche environment translated to a decrease in 
neurogenesis in the α-CX3CR1 group. In rats that were treated for 14 days, a significant decrease 
(t(7)=2.690; p=0.0311; Fig. 16F) was found in the number of DCX+ cells in the α-CX3CR1 group 
compared to the non-immune IgG treated group. 
FKN is necessary to maintain microglia in an unactivated state. FKN/CX3CR1 has 
been proposed to maintain microglia in a quiescent resting state. The expression of MHC Class II 
on microglia is induced when the cell becomes activated. To determine if microglia became 
activated following the CX3CR1 blocking antibody treatment, the number of cells expressing MHC 
Class II was quantified using the marker OX-6. In the young adult rats the entire hippocampus 
was used as the region of interest in order to sample a large enough population of cells, due to 
the few OX-6+ cells in young adult control rats. Following 7 days (F(3,18)=3.644; p=0.0326; 
Fig.18A) or 15 days (t(8)=2.653; p=0.0291; Fig.18B) of treatment there was a significant effect in 
the number of OX-6+ cells. At 7 days, the group of rats that were treated with the α-CX3CR1 and 
the heat-inactivated IL-1Ra (HI-IL-1Ra+ α-CX3CR1; n=5) had significantly more OX-6+ cells 
compared to the non-immune IgG treated rats with either the inactive IL-1Ra (HI-IL-1Ra+IgG; 
n=5) (t(8)=2.591; p=0.0321) or active IL-1Ra (IL-1Ra+IgG; n=5) (t(8)=2.412; p=0.0423). The group 
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that received the α-CX3CR1 blocking antibody along with the active IL-1Ra was not significantly 
different from any of the other groups (IL-1Ra+ α-CX3CR1; n=6).  At 15 days a similar significant 
increase in the number OX-6+ cells was found in the α-CX3CR1 treated group compared to the 
non-immune IgG treated group  
Aging is associated with increased activation of microglia. We hypothesized that a portion 
of the microglia activation might be a result of a decreased inhibitory signaling by FKN. To test 
this hypothesis, we quantified the number of OX-6+ cells in SGZ/GCL only. In the aged rats there 
was a large enough population of OX-6+ cells in this region of interest to sample adequate 
number of cells following treatment with FKN or HI-FKN. After 14 days (Exp.2) of FKN treatment, 
a significant decrease in the number of activated OX-6+ cells was found (t(8)=3.030; p=0.0163; 
Fig.18C) in the FKN group compared to the HI-FKN group. Previous studies have shown a 
negative correlation between the number of activated microglia and the amount of new cells that 
are born (Ekdahl et al., 2003; Bachstetter et al., 2008); a correlation analysis was conducted to 
determine if similar effect was observed following FKN treatment. In the aged rats, after 14 days 
of treatment with FKN, the number of OX-6+ cells was found to significantly negatively correlate 
(r(9)=-0.7425; p=0.0219; Fig.18D) with the number of IdU+ cells (Exp.2; Fig.12E). We did not find a 
significant correlation between the number of CldU+ cells or DCX+ cells and the number of OX-6+ 
cells (data not shown). Furthermore, in aged rats treated for 7 days with FKN we did not find any 
differences in the number of OX-6+ cells (data not shown). 
Discussion  
Two questions were addressed by the present study: Is CX3CR1/FKN signaling important 
for maintaining adult hippocampal neurogenesis? Could a disruption in CX3CR1/FKN signaling 
contribute to the age-related decline in neurogenesis? We demonstrated three main findings: first, 
loss of function of CX3CR1 in young adult rodents, mice and rats, resulted in a significant 
decrease in hippocampal neurogenesis; second, administration of exogenous FKN reversed the 
decline in neurogenesis associated with aging; third, IL-1Ra protected against the decrease in 
hippocampal neurogenesis induced by blocking CX3CR1 function.  
Our results suggest that neurons which are the major producers of FKN, and microglia which 
express CX3CR1 are actively involved in a cross-talk to regulate the production of new neurons. 
During development the expression of FKN in the brain has been shown to increase nearly 10 
fold in four week old mice compared to one day old mice (Labrada et al., 2002). In our study, we 
found that FKN expression was absent on immature neurons, suggesting that FKN might be 
important in protecting mature neurons from the consequences of overactive microglia. It is also 
possible that mature neurons, through an indirect mechanism, could communicate with microglia 
to regulate the addition of new neurons into the mature circuit. This could occur via IL-1β 
decreasing the proliferation of the NPCs. Furthermore, FKN might also be involved in the removal 
of apoptotic cells, as FKN has been shown to enhance phagocytosis of apoptotic cells (Fuller and 
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Van Eldik, 2008). Removal of apoptotic cells is an important mechanism to make room for new 
cells to be added, and to prevent secondary necrosis of the apoptotic cell which occurs if dead 
cells are not quickly removed.  
FKN is anchored to the cell membrane, but can be cleaved off the membrane by 
metalloproteinase 10 (ADAM10) (Hundhausen et al., 2003) or by TNF-a converting enzyme 
(TACE / ADAM17)(Garton et al., 2001). FKN signaling, when decreased beyond a physiological 
level, as in the case of young rats treated with α-CX3CR1, was observed to decrease 
neurogenesis. On the other hand, when FKN signaling was already decreased, as we observed 
in the aged control rats, a further loss did not affect neurogenesis. Similarly in the young control 
rats, in which FKN levels are normal, addition of exogenous FKN did not alter neurogenesis. 
However, our current study doesn’t address if the membrane or shed form of FKN might have 
unique roles in regulating neurogenesis. Therefore, future studies are warranted to discern if 
there are different mechanisms of actions produced by the different forms of FKN.  
CX3CR1/FKN signaling is proposed to keep microglia in a non-proinflammatory state (Cardona et 
al., 2006), as inhibition of FKN/CX3CR1 function has been shown to increase microglial activation 
and increase production of TNFα and IL-1β (Zujovic et al., 2000; Mizuno et al., 2003; Cardona et 
al., 2006). We found that inhibition of FKN/CX3CR1 function increased microglia activation. This 
finding is in agreement with our hypothesis that disruption of CX3CR1 function leads to an 
increase in microglia activation, which could be ultimately responsible in negatively regulating 
neurogenesis. However, we did not find increased microglia activation as measured by MHC-II 
expression, in the CX3CR1GFP/GFP mice compared to the heterozygote littermates (data not 
shown). A possible explanation could be that permanent loss of CX3CR1 since birth results in 
compensatory changes in the expression of cell surface markers of microglia activation. An 
additional discrepancy was found in the aged rats treated with FKN for 7 days, where we saw an 
increase in proliferation but no changes in the number of MHC-II+ cells, or DCX+ cells. Thus, it is 
possible that FKN does not exert its effect directly through microglia.  Alternatively, alterations in 
MHC-II expression may not be the best indicator of the activation state of microglia induced by 
alteration in FKN/CX3CR1 axis. This may be because MHC-II expression can occur in activated 
microglia which can be classically activated to produce pro-inflammatory cytokines, as well as in 
microglia that are alternatively activated to produce growth factor and anti-inflammatory 
cytokines. However after 14 days of FKN treatment there was a significant reduction in the 
number of MHC class II+ cells. Furthermore, we found a negative correlation between the number 
of MHC-II+ cells with the number of IdU+ cells. While we cannot rule out the possibility that other 
pathways are involved in the effects observed in our study, our data in aged rats strongly indicate 
that FKN/CX3CR1 suppression of microglia activation, at least in part, modulates hippocampal 
neurogenesis in aged rats. 
Aging is associated with chronically elevated levels of IL-1β in the hippocampus (Gemma 
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and Bickford, 2007). IL-1β has been shown to act directly at the NPC via the IL-1R1 to block cell 
cycle progression and thereby decrease proliferation (Koo and Duman, 2008).  Moreover, we 
have recently shown that reducing the levels of IL-1β in aged rats is able to reverse some of the 
age-related decreases in neurogenesis (Gemma et al., 2007b).  CX3CR1 regulates the PI3K 
pathway in microglia resulting in inhibiting the production of IL-1β (Re and Przedborski, 2006). 
We found disruption of FKN signaling by a blocking antibody to the FKN receptor CX3CR1 
caused an increased production of IL-1β.  In the young adult rats we found that IL-1Ra 
completely reversed the decrease in proliferation and neurogenesis that resulted after blocking 
CX3CR1, suggesting that the effects of FKN on NPC proliferation are mediated through inhibition 
of IL-1β.  
Several studies have shown that FKN can have direct effects on neurons in vitro (Meucci et al., 
1998; Meucci et al., 2000; Tong et al., 2000). Using the GFP expression in the CX3CR1+/GFP mice 
we found that the receptor for CX3CR1 was not found on neurons in the GCL, which confirmed 
earlier findings in vivo that found CX3CR1 expression only in microglia (Harrison et al., 1998; 
Jung et al., 2000; Cardona et al., 2006). Moreover, it has been recently shown that the survival 
effects of FKN on primary neuron al culture was dependent on microglia (Lauro et al., 2008). 
These results suggest that FKN acts via the microglia expressed CX3CR1 to regulate IL-1β which 
then acts on the NPCs and neurons.  
The second major finding of this study is an age-related disruption of FKN/CX3CR1 
signaling. Cardona et al. (06) demonstrated in a number of models of neurodegeneration that loss 
of neuron-microglia interactions by disruption of FKN/CX3CR1 signaling results in increased 
microglia neurotoxicity and an associated worsening in disease pathology. It is unclear if the 
disregulation of FKN signaling observed in our study is a cause or consequence of the increased 
activation of microglia and neuroinflammation that occurs as a result of normal aging.  Levels of 
FKN in aged control rats were decreased in the hippocampus compared to young adult rats. The 
lack of alteration in FKN mRNA suggests that post-translational changes are responsible for the 
age-related decrease in FKN. Therefore, as a result of normal aging, the alterations in 
FKN/CX3CR1 signaling are mostly likely a result of changes in ligand levels or post-translational 
processing and not alterations to the receptor as administration of exogenous FKN restored the 
age-related loss in neurogenesis. Age-related changes in the FKN/CX3CR1 axis have been 
characterized in other scenarios. There are at least two common single nucleotide 
polymorphisms in the promoter region of CX3CR1 which cause reduced CX3CR1 function, 
including decreased adhesion, signaling, and chemotaxis of CX3CR1+ cells. These 
polymorphisms have been associated with reduced risk for atherosclerosis (McDermott et al., 
2003) and increased risk of age-related macular degeneration (Tuo et al., 2004; Combadiere et 
al., 2007). Moreover, our results are in agreement with data obtained in Alzheimer’s disease 
patients in which lower levels of soluble plasma FKN were correlated with lower mini-mental 
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status examination score(Kim et al., 2008).  Additionally, APP transgenic mice showed a 
decrease in neuronal levels of FKN at 9 months of age (Duan et al., 2008). 
Conclusion 
Microglia have been demonstrated to be both pro and anti-neurogenic depending upon 
their activation state. This study demonstrates that neurons may actively regulate microglia in the 
neurogenic niche, and are not necessarily passive actors to the effects of microglia. However with 
age, the dialog between neuron and microglia via FKN appears to be disrupted, but can be can 
be re-established through the addition of recombinant FKN. Inflammation is believed to be a 
contributing factor to the pathogenesis of a number of neurodegenerative diseases, many of 
which are age-related, including: Alzheimer’s disease, Parkinson’s disease, and age-related 
macular degeneration. Understanding the mechanism by which age-related alterations in the 
inflammatory response contribute to the progression of the aforementioned neurodegenerative 
diseases is key to developing therapeutic interventions for the age-related neurodegenerative 
condition.  
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Figure 9: CX3CR1GFP/GFP mice have diminished hippocampal neurogenesis. (A) 
Unbiased stereology revealed a significant decrease (p=0.0062) in the number of DCX+ cells in 
the hippocampus of adult male CX3CR1GFP/GFP mice (n=5) compared to heterozygote control 
(n=4). (B) Quantification of the number of cells that were proliferating during the proceeding 24 
hours, as determined by the incorporation of BrdU, was significantly fewer (p=0.026) in the 
CX3CR1GFP/GFP mice (n=9) compared to control (n=6). (C) CX3CR1 (GFP) and dapi (blue), 
demonstrate the localization of the CX3CR1 cells in the dentate gyrus. (D) Localization of 
CX3CR1 (GFP) cells was not found in NeuN+ cells (magenta) or in GFAP+ cells (blue), and only 
rarely in BrdU+ cells (red). (E). Low power photomicrograph of DCX+ cells (red) and CX3CR1 
(GFP) cells are also shown in higher power in maximum projection of confocal z-stack (F) Arrow 
indicated CX3CR1 (GFP) cells that are in close proximity to the DCX cells. 
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Figure 10: Proliferation is 
decreased by α-CX3CR1. Three ages of 
male F344 rats were treated with α-
CX3CR1 or the IgG control for 7 days via 
an osmotic minipump to the left lateral 
ventricle. On day 6 of treatment BrdU 
was injected twice 8 hours apart. The 
animals were sacrificed on day 7. (A) 
Quantification of the number of BrdU+ 
cells in the subgranular zone, in the 
young adult rats revealed a significant 
decrease (***p=0.0009) in the number of 
adult young rats following α-CX3CR1 
(n=6) compare to IgG control (n=6). In the 
middle aged rats and the aged rats there 
was no significant differences in the 
number of BrdU+ cells in the IgG control 
group compare to the α-CX3CR1 treated 
group. (B) The decrease in BrdU+ cells in 
the young rats treated with α-CX3CR1 
(n=4) compare to IgG control (n=3) was 
confirmed by Ki-67, as a significant 
decrease was also found in the number 
of Ki-67+ cells (*p=0.0156). Confirming 
the BrdU data, in the aged rats no 
difference in the number of Ki-67+ cells 
was found. (C) The number of DCX+ 
cells was also found to be significantly 
decreased (*p=0.0466) in the young adult 
rats following α-CX3CR1 treatment (α-
CX3CR1 n=3; IgG n=4), but no effect was 
found in the middle aged rats or old aged. 
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Figure 11: FKN reverses the age-
related decrease in neurogenesis. 
(A) Timeline: In experiment 1 
treatment lasted for 7 days, with 
injections of BrdU occurring at day 6. 
In experiment 2, treatment lasted for 
14 days, with injections of CldU 
occurring at day -1 and injections of 
IdU occurring at day 6. BrdU was 
used to study the affects of the 
treatment on proliferation of 
hippocampal NPC. CldU was used to 
study the affects of treatment on the 
cells born prior to the treatment. IdU 
was used to study the affects of 
survival of the cells born after 
treatment and to make direct 
comparisons with BrdU data. (B) A 
significant increase (p=0.0248) in 
proliferation (FKN n=6; HI-FKN n=6) 
but not in the number of DCX+ cells 
(FKN n=4; HI-FKN n=6) (C) was 
found in the aged treated with FKN 
for 7 days. (D) In the second 
experiment, in the cells born before 
treatment began (labeled with CldU) 
and lived for 15 days no difference 
was found between groups (FKN 
n=5; HI-FKN n=4). When the cells 
were labeled at the same time point 
as BrdU (B) with IdU a significant 
increase (p=0.0065; E) in number of 
IDU+ cells was found in the FKN treated group (FKN n=5; HI-FKN n=4), (H) which appeared to 
translated to the significant increase (p=0.0116) in the DCX+ as the two makers were strongly 
correlated (r=0.933; p=0.0002) (I).  
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Figure 12: FKN exerts proliferative effects in aged rats. Rats were injected with BrdU 
on day 6 of a 7 day treated of FKN (30ng/d) or a heat-inactivated (HI)-FKN control. (A). No 
differences were found in the number of BrdU+ cells in the young or middle aged animals 
between treatment groups. As shown in figure 2B, in the aged rats a significant increase in the 
number of Brdu+ cells was found (p=0.0248) in the FKN treated rats compare to the control rats. 
(B) Quantification of DCX+ cells demonstrated an absence of a treatment effect in all three ages 
after 7 days of treatment. BrdU and DCX data from the 22 mo old rats was also presented in Fig 
2B and 2C respectively, and was re-presented in the supplementary data for comparison 
purposes.  
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Figure 13: Expression of FKN in the hippocampus. Quantification of protein (A) and 
mRNA (B) levels of FKN in the hippocampus of young adult and aged rat, demonstrated a 
significant decrease in protein levels of FKN (p=0.0005) (n=9 per group), but not in mRNA levels 
(n=6 per group). (C) FKN expression (green) was not found on Tuj1+ (red) cells, but was 
expressed on the majority of the cells (dapi: blue) in the GCL. (D) and (E), shows low and high 
magnification respectively, of Ki-67 staining (red) and FKN staining (green), with dapi (blue). 
Similar to the Tuj1+ cells, the Ki-67+ cells also lack FKN expression.  
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Figure 14: CX3CR1 blocking antibody increases hippocampal IL-1β levels. In 3 
month old male rats treated for 28 days with the blocking antibody we found a significant increase 
in IL-1β protein levels compared to non-immune IgG or Saline control animals. (††p=0.0023 Saline 
vs. IgG) (***p=0.0003 saline vs. α-CX3CR1) (*p=0.039 IgG vs. α-CX3CR1) (Saline n=8; IgG n=4; 
a-CX3CR1 n=5). 
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Figure 15: IL-1Ra 
reverses the effects of α-
CX3CR1. To determine if the 
decrease neurogenesis caused by 
blocking antibody to α-CX3CR1 
was mediated by IL-1β we infused 
IL-1Ra along with the blocking 
antibody for 7 days of treatment. 
On day 6, young adults rat were 
injected with BrdU. Gray bars are 
the groups that received heat-
inactivated IL-1Ra. White bars are 
groups that received active IL-
1Ra. (A) In the α-CX3CR1/HI-IL-
1ra group, there was significantly 
fewer BrdU+ cells then the three 
other groups which were not 
different from each other. (B) IL-
1ra blocked the decrease in DCX+ 
cells caused by α-CX3CR1. In the 
non-immune IgG group IL-1Ra 
(white) caused a significant 
decrease in the number of DCX+ 
cells compared to the IL-1Ra 
inactive control (grey). (C) A 
representative photomicrograph of the BrdU (green) and DCX (red) double labeling. Following the 
14 day infusion paradigm (see Fig.3A), (D) we found a significant (p=0.0091) decrease in the 
number of CldU+ cells which were born the day before we started infusion in the α-CX3CR1 (n=4) 
compared to the non-immune IgG group (n=5). (E) In the 14 day experiment, a significant 
decrease (p=0.0406) was also found in the number of IdU+ cells in the α-CX3CR1 (n=4) 
compared to the non-immune IgG group (n=5). (F) Quantification of the number of DCX+ cells 
also demonstrated a significant (p=0.0311) decrease following treatment in the α-CX3CR1 (n=4) 
compared to the non-immune IgG group (n=5). 
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Figure 16: CldU colocalizes with NeuN.CldU+ cells (red) were found to co-localize with 
NeuN+ cells (green) in the IgG treated group (A) and α-CX3CR1 treated group (B).
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Figure 17: FKN signaling regulates microglia activation. Quantification of the number 
of OX-6+ cell, which is a marker for MHC class II, (A) we found in the rats that received the 
blocking antibody with an inactive IL-1Ra (gray) a significant increase in the number of OX-6+ 
cells compared to the two non-immune IgG groups. (B) After 15 days of blocking antibody 
treatment in the young rats a similar significant increase in the number of OX-6+ cells was found 
in the young α-CX3CR1 treated rats (n=5)  compared to the non-immune IgG treated rats (n=5). 
(C) In the aged rats after 14 days of treatment with FKN a significant decreased (p=0.0163) the 
number of OX-6+ cells was found in the α-CX3CR1 treated rats (n=6) compared to the non-
immune IgG treated rats (n=4). (D) The number of OX-6+ cells was also found to significantly 
correlated with the number of IDU+ cells(r(9)=-0.7425; p=0.0219)
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Conclusions: The Role of neuroinflammation in regulating the age-related decline 
in neurogenesis: could restoring the balance rescue neural plasticity 
Introduction 
Deteriorations in cognitive function occur as a consequence of growing old in the 
absence of clear neurological damage or disease. Aging is the background in which many 
neurodegenerative diseases manifest; therefore, in understanding of the age-related alterations 
that occur in the central nervous system (CNS) are an important consideration when developing 
therapeutic interventions for age-related neurodegenerative diseases. Age-associated memory 
impairments, should not be considered unavoidable. On it’s on merit, strategies for ‘successful’ 
aging’ are worthy of scientific investigation.  
The hippocampus is critical structure for normal memory functions. Alterations in 
neural plasticity, not cell loss, appear to be responsible for the age-related alterations in 
hippocampal dependent cognitive function. There are numerous subtle age-related alterations in 
neural plasticity (for review see: (Burke and Barnes, 2006)). Adult neurogenesis is one form of 
neural plasticity that is dramatically limited with age.  
Adult neurogenesis 
The majority of the neurons in the adult central nervous system (CNS) are postmitotic. In 
the absence of pathology, neurons are believed to remain postmitotic, and survive thought the 
lifespan of the organism. However, an ongoing neurogenesis continues to occur in two germinal 
centers of the CNS: the subventricular zone (SVZ), and the subgranular zone (SGZ) of the 
dentate gyrus (DG) of the hippocampus. Adult neurogenesis is a process that involves a 
continuum of developmental stages. The final result of the process is that a few newly born cells 
are added to the existing neuronal circuitry. Adult hippocampal neurogenesis occurs in a region 
called the SGZ, which is roughly defined as a two cell diameter band on the hilus side of the 
granule cell layer (GCL). Proliferation of the neural stem/progenitor cells (NPCs) produces a pool 
of immature cells, the majority of which will become neurons. Following the generation of the 
daughter cell, the postmitotic cell goes through an early survival phase. During this phase the 
number of surviving neurons can vary greatly depending on the strain of animals used and can be 
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as great as ~ 75% or as few as 25% of the amount of proliferating cells (Kempermann et al., 
1997c). Moreover, in the young adult rodent, most of the regulation of neurogenesis occurs in the 
early survival phase and not in the proliferative phase (Kempermann et al., 2006). The newly born 
cells the majority of which do become neurons, go through a migratory phase (Kempermann et 
al., 2003b), which occurs while the cells are becoming functionally mature. The adult-born 
neurons become morphologically and physiologically fully mature and indistinguishable by 6 to 8 
weeks after birth in the young adult rodent (van Praag et al., 2002; Esposito et al., 2005; Zhao et 
al., 2006; Toni et al., 2008). Finally, an additional phase of neurogenesis appears to be the 
eventual death of the cell, as a continual turnover of cells both mature and immature is necessary 
to 'make room' for the addition of more cells.  
Adult neurogenesis and memory are they related? 
The addition of new neurons into the hippocampus, a region of the brain important for 
learning and memory, has elicited interest in understanding if and how the addition of new 
neurons would contribute to cognitive function (Leuner et al., 2006; Aimone et al., 2009). 
However, the involvement of neurogenesis, in cognitive function is complex. Correlations, 
between genetic and environmental alterations, were initially used to justify the importance of 
neurogenesis in cognitive function. For example environmental enrichment (EE) has been shown 
to enhance memory and increase neurogenesis (Kempermann et al., 1997b). However, following 
irradiation to block neurogenesis, the behavior improvements of EE on spatial learning in the 
Morris water maze (MWM) was found to be independent of neurogenesis (Meshi et al., 2006). In 
a subsequent experiment that used irradiation to block neurogenesis without EE, blocking 
neurogenesis was found to impair contextual fear conditioning with no effect on MWM (Saxe et 
al., 2006). Using an inducible mouse model in which NPC are selectively eliminated by over-
expressing the pro-apoptotic protein Bax only in nestin expressing cells found that neurogenesis 
was required for MWM but nor for contextual fear conditioning (Dupret et al., 2008).  
Often the contradictions in fact support the role of neurogenesis in cognition. A recent 
study by Dupret et al (2007) demonstrated that not only is the addition of new neurons into the 
hippocampal circuit important for cognition but so is the removal of granule cells important for 
cognition (Dupret et al., 2007). Like the hippocampus, several thousand newly generated neurons 
are added to the olfactory bulb (OB) (Lledo and Lagier, 2006). In the OB, learning of olfactory 
information also appears to be coupled to the survival of some newly generated neurons and the 
removal of others (Mouret et al., 2008). 
Despite the often contradictory findings, numerous studies have shown that the de novo 
production of neurons in the hippocampus is physiologically relevant for cognitive function (For 
review see: (Leuner et al., 2006; Drapeau and Nora Abrous, 2008)). From the numerous studies 
that have been done the involvement of neurogenesis in cognitive function can be classified into 
3 groups: 1) effects on proliferation, 2) effects on survival, and 3) effects on cell death. It appears 
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that alterations in one or more of these 3 aspects of neurogenesis can impact cognition. 
Neurogenesis and aging: is neurogenesis involved in age-related cognitive decline. 
Neurogenesis appears to continue throughout the lifespan, however studies in rodents 
describe a nearly linear decline in neurogenesis as a function of age.  Despite the thousands of 
new neurons that are born every day in the young adult hippocampus, with age a greater then 40 
fold decrease can be seen in the number of new neurons that are added into the aged 
hippocampus. A peak in neurogenesis occurs during adolescents, after which point, there is a 
continuous decline in neurogenesis until senescence when very few new cells are added to the 
aged brain (Ben Abdallah et al., 2008). The decline in neurogenesis has led to speculation 
concerning the contribution of neurogenesis to the impairments in cognitive function that occur 
during normal aging? A troubling issue arises in that the decline in neurogenesis well precedes 
any age-related cognitive decline. The largest decrease in neurogenesis occurs between 7.5 
months and 12 months of age in rats (Rao et al., 2006). A threshold hypothesis has been 
presented to account for this discrepancy. The basic concept of the hypothesis is that the 
decrease in neurogenesis with age does not impact cognition until the level of neurogenesis 
reaches some physiologically minimum number of cells.  
Drapeau et al. (2003) addressed this threshold hypothesis by using aged rats that are 
‘good’ or ‘bad’ learners. Not all aged rats have cognitive-impairment, at least as measured by the 
spatial learning task of the Morris water maze (Gallagher et al., 1993). Numerous studies over the 
years have used the natural variation in cognitive function in aged rats to investigate if there are 
differences in between the rats that demonstrate impaired cognition compare to the rats whose 
cognitive performance is equal to that of a young rat. Drapeau et al (2003) exploited these natural 
variations in cognitive function to ask the question if neurogenesis could be involved in age 
induced cognitive impairments. The results of their study demonstrated that rats that were defined 
as being cognitively un-impaired had increased proliferation of the NPC and more neurogenesis 
then cognitively impaired rats. However, while the cognitively intact rats had more neurogenesis 
than the impaired rats, the cognitively intact rats still had great deal less neurogenesis then the 
young rats. Moreover, in the young rats then amount of neurogenesis did not correlated with 
cognitive performance (Drapeau et al., 2003). The results of Drapeau et al. (2003) were directly 
contradicted by Bizon et al. (2004) who showed that the aged cognitively impaired rats had more 
neurogenesis (Bizon et al., 2004). Moreover, other reports have showed that neurogenesis does 
not correlate with spatial learning (Bizon and Gallagher, 2003; Merrill et al., 2003).  
Where do we put all these new neurons? 
An estimated 9000 new neurons are added each day to the hippocampus (cammeron 
and Mckay 2001), but the total number of neurons in the hippocampus has been shown to be 
stable over the entire lifespan, including in elderly. From the first month of life, to one year of age 
the number of granule cells in the dentate gyrus does increase in rodents (Bayer et al., 1982). 
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However the increase in size is no where near the amount that would be expected, based upon 
the number of cells born in the SGZ. Moreover, despite the decrease in neurogenesis with age 
the total number of granule cells does not decrease in the aged rat. Therefore it appears that 
tissue homeostasis (total number of granule cells) in the dentate gyrus appears to be tightly 
regulated. To maintain tissue homeostasis neurogenesis must be coupled to a process of 
programmed cell death (PCD).  This process occurs in tissues thoughtout the body, but until 
discovery of adult neurogenesis, the central nervous system (CNS) was believed to be exempt 
from this process. In fact, excluding disease or injury, the neurons we are born with are presumed 
to be the same neurons that we will die with. However, in the hippocampus and in the SVZ 
neurons are born every day, requiring the homeostatic death and removal or older neurons in 
these two neurogenic regions (Biebl et al., 2000).  
BCL-2 (B-Cell Leukemia 2) is the prototypical member of the Bcl-2 family of apoptotic 
regulatory proteins. BCL-2 is an anti-apoptotic protein. The balance between the pro vs anti- 
apoptotic BCL-2 family members following an apoptotic stimuli determines if the cell lives or dies 
(Oltvai et al., 1993). Bax and Bak are two of the many members of the pro-apoptotic of the BCL-2 
family.  Using neuronal cell cultures from Bak-/-Bax-/- mice it was found that NPC require Bak and 
Bid to induce excitotoxic PCD; whereas, mature neurons do not require Bak and Bid to induce 
PCD (Lindsten et al., 2003). Sun et al. (04) was the first to investigate the biochemical pathways 
that regulate the PCD in adult-born neurons, through the use of Bax deficient mice.  The Bax 
deficiency resulted in an absence of apoptosis in the adult DG, without any alterations in the 
production of new neurons. In the wild type mice the number of neurons in the DG remained 
stable from 2 months to 12 months of age. In comparison, there was an age-dependent increase 
in the number of cells in the DG in the Bax deficient mice (Sun et al., 2004).  Kuhn et al. (05) 
replicated the findings of Sun et al. (04) through the overexpression of BCL-2 in transgenic (Tg) 
mice .  The overexpression of BCL-2 reduced by did not completely block apoptosis. The 
increase in neurogenesis was also not as dramatic as that seen following Bax deficiency.  The 
total number of cells in the GCL was also increased in the BCL-2 Tg mice (Kuhn et al., 2005). 
The BCL-2 Tg mice have also been shown to have cognitive deficits (Rondi-Reig et al., 2001). 
These results support the notion that the loss of neurons is important for cognition (Dupret et al., 
2007).  
Microglia Regulation of cell death in developmental and adult neurogenesis 
Microglia are immune cellular component and the professional phagocyte of the brains. 
Recognition of pathogen associated molecular pattern (PAMPs) and is recognized by microglia 
pattern-recognition receptors (PRR). The most common PAMP used experimentally, particularly 
in neuroscience research, is lipopolysaccharide (LPS). LPS a major component of the outer 
membrane of gram-negative bacteria and is used to induce inflammation in the CNS to 
understand the involvement of the immunity in a particular condition. LPS can be very useful, as a 
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way to induce a replicable and specific immune response. However, LPS induces a microbial 
defense immunity, resulting in the activation of pro-inflammatory pathways, producing 
inflammatory mediators including cytokines and chemokines. The response to eliminate the 
‘danger signals’ does not discriminate and will also cause damage to the uninfected tissue. 
Besides the PRRs, microglia also express a number of scavenger receptors that are involved in 
the recognition and removal of dead cells and other cellular debris; such as Aβ.  
In many ways the process of adult neurogenesis recapitulates events during embryonic 
development. During development of the nervous systems, in excess of neurons are born then 
ultimately survive into adulthood. (Oppenheim, 1991).  It has been hypothesized that during 
development the excess of cells are produced to allow for a competition between the newly born 
neurons for trophic support from other neurons and glia (Oppenheim, 1991). The competition for 
trophic support, results in a proportion of the cells being eliminated.  The ‘pruning’ of the excess 
cells, presumably by some form of PCD, leaves the cell which received the adequate trophic 
support to survive and be integrated in the neuronal circuit (Oppenheim, 1991). A similar process 
is believed to occur during adult neurogenesis as well.  
During development the dead cells are recognized and removed phagocytes. In the brain 
the dead cells are recognized by microglia and are removed (Mallat et al., 2005). The primary 
‘eat-me’ signal expressed by dying cells is phosphatidylserine (PS) on the outer leaflet of the 
plasma membrane of the apoptotic cells (Fadok et al., 1992). Severe developmental brain 
malformations occur if microglia are not able to recognize PS due to genetic deletion of PS 
receptor (Li et al., 2003). Some the ‘eat-me’ signals expressed by dying cells are shared with 
PAMP, and have therefore been called, apoptotic cell associated molecular pattern 
(ACAMPs)(Savill et al., 2002). While both PAMPs and ACAMPs are recognized by the 
macrophage through the PRR, the response by the macrophage is distinct. Recognition of a 
PAMPs by a macrophage promote an inflammatory response; whereas, recognition of an ACAMP 
inhibits inflammation (Stuart and Ezekowitz, 2005). This is important for the ‘silent’ removal of the 
apoptotic cells (Medzhitov, 2008).  
To ensure healthy cells are not the victims of over active microglia, healthy cells present 
an additional class of inhibitory signals which have been called ‘don’t eat me’ signals or self 
associated molecular patterns (SAMP). The SAMPs expressed by neurons include CD200, 
CD47, and fractalkine among others.  
Microglia are not only involved the phagocytosis of the apoptotic cells, but also contribute 
to demise of the apoptotic cells.  If the dying cell does not present the ‘kill-me’ signals, PCD can 
be stopped and the cells will survive (Hoeppner et al., 2001; Reddien et al., 2001). During 
development two models have shown that microglia responded to the 'kill-me' signal presented by 
neurons with a respiratory release of ROS to kill the cells. This has been shown in the cerebellum 
and the hippocampus (Marin-Teva et al., 2004; Wakselman et al., 2008). In the hippocampus the 
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process was CD11b and DAP12 mediated (Wakselman et al., 2008). As described earlier, the 
removal of excess neurons is important to cognitive function as the addition of neurons. Microglia 
have an important role in the removal (pruning) of excess neurons. 
Inflammation and adult neurogenesis 
Two seminal studies, published simultaneously, a number of years ago showed that 
inflammation tightly regulates neurogenesis (Ekdahl et al., 2003; Monje et al., 2003).  Ekdahl et 
al. (03) used LPS that they delivered into the cortex continuously by an osmotic mini pump. After 
28 days of LPS there was a dramatic activation of ED-1+ cells. ED-1 (CD68) is a member of the 
scavenger receptors, which is highly expressed on monocytes and some tissue macrophages. 
The expression of ED-1 on microglia is normally absent, but can be induced following an 
inflammatory insult, which is what was found after 28 days of intracortical infusion of LPS.  In the 
young adult rat, LPS-induced inflammation resulted in an 85% reduction in the number of new 
neurons born during the inflammatory insult (Ekdahl et al., 2003).  Monje et al. (03) also found 
that LPS given systemically also cause in increase in microglia activation and a decrease in 
neurogenesis, which could be prevented by the nonsteroidal anti-inflammatory drug (NSAID) 
indomethacin. Toll-like receptor (TLR)-4 is the specific receptor for LPS. Expression of TLR-4 in 
CNS glial cells was found to be limited to microglia (Lehnardt et al., 2002). NPC and mature 
neurons have been shown to express TLR-4 (Rolls et al., 2007; Tang et al., 2007); thus, it is 
possible that the anti-neurogenic effects of LPS could be independent of microglia.  
While TLRs (particularly TLR-4) often acts a co-receptor in many immune responses, the 
immune response to bacteria, virus, or parasite, is quite different then that started from tissue 
damage. Monje et al (03) found that inflammation was also at least in part responsible for the 
decrease in neurogenesis after irradiation. Following irradiation there was an increase in 
microglia activation that could be prevented by treatment with NSAID. The treatment with the 
NSAID was also able to prevent anti-neurogeneic effects of irradiation.  Microglia besides being 
responsible for protecting the CNS from invading pathogens, are also important for removing 
cellular debris. Microglia are the professional phagocytes of the brain.  
Microglia would appear to be the optimal cell to regulate neurogenesis. Microglia perform 
3 key functions that would make them key in regulating neurogenesis. First microglia have the 
potential to be neurotoxic though the production of reactive oxygen species thereby being 
involved in the removal of mature or immature cells(Marin-Teva et al., 2004; Wakselman et al., 
2008).  Microglia are also important for the phagocytosis of the dead cells (Mallat et al., 2005). 
The second way that microglia can be involved in regulating neurogenesis is through the 
production of cytokines. This is particularly true for the key innate cytokines IL-1β and TNF-α, with 
activated microglia being the major source of TNF-α and IL-1β in the CNS (Gebicke-Haerter, 
2001)(Shaftel et al., 2008). At low concentrations TNF-α, induced proliferation of NPC, but at 
higher concentrations TNF-α induced PCD (Bernardino et al., 2008). NPC cultures have been 
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shown to have constitutively express the TNF-α RI and TNFRII (R. E. Iosif et al., 2006). TNF-α 
induced apoptosis in the NPC is dependent on TNFRI (Sheng et al., 2005). IL-1β can also directly 
suppress neurogenesis by blocking the production of cyclic dependent kinesis (Iosif et al., 2006; 
Koo and Duman, 2008). Inflammation also alters the way the new neurons integrate into the 
existing neuronal circuit (Jakubs et al., 2008). The third way in which microglia can regulate 
neurogenesis is by a pro-repair/pro-neurogenic mechanism. Microglia are able to produce a 
number of growth factors including IGF-1 and BDNF which have been shown to promote 
neurogenesis (For review see:(Ziv and Schwartz, 2008)).  
Age-related cognitive impairment: is it a numbers game? 
The dramatic decrease in neurogenesis with age has led to much speculation concerning 
the extent in which the decline in neurogenesis contributes to age-related cognitive impairments.  
During the 1990’s, when adult neurogenesis was accepted by the scientific community the 
commonly held view was the total number of newly formed mature neurons would correlate with 
cognitive performance. To this end, the age-related decline in the total number of new neurons 
was believe to, at least impart contribute to the cognitive decline that occurs during the course of 
normal aging.  As discussed earlier, the result of Drapeau et al. (2003) suggest the total number 
of new neurons may indeed be critical for cognitive performance. However, it has become 
increasingly clear that in the young adult where the addition of new neurons is in abundance, it is 
not so much that total number of cells that is important, but the experience-dependent regulation 
of addition and removal of neurons that is important for certain types of cognitive function.  The 
same dynamic holds true in the aged brain, where rats that are aged-unimpaired demonstrate 
experiences dependent addition and removal of new neurons (Drapeau et al., 2007). 
The primary cause for the decrease in neurogenesis in aging is due to a decrease in 
proliferation of the NPC (Hattiangady and Shetty, 2008).  During development an excess of cells 
are born with the ‘fittest’ cell surviving. A similar process occurs in young adult, where the majority 
of the experience-dependent regulation of neurogenesis occurs as a result of survival of the 
‘fittest’ cell. If an ‘unfit’ cell is forced to survive by inhibiting PCD memory has been shown to be 
impaired (Dupret et al., 2007). What about with age where the majority of the regulation of the 
number of new neurons occurs at the proliferation stage and not at the survival phase? Could the 
change at which point neurogenesis is regulated be responsible for the age-related cognitive 
decline? With fewer cells, there is less competition, which could allow the survival of an ‘unfit’ cell. 
There is no direct experimental evidence to support or reject either hypothesis. However, Bizon et 
al. (2004) found that aged-impaired rats had more new neurons. The results of Bizon et al. (2004) 
has led to the suggestion that neurogenesis is not involved in neurogenesis. However, in 
alternative hypothesis of the findings of Bizon et al. (2004) could be that in the aged-impaired rats 
‘unfit’ cells survive. The survival of ‘unfit’ cells could be a compensatory mechanism in the aged 
impaired rats to overcome for losses in other forms of synaptic plasticity.  Alternatively, the aged-
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impaired rats may be deficient in the removal of ‘unfit’ cells resulting in abnormal connections that 
impair memory.  
Conclusion 
It is known that with aging and age-related neurodegenerative diseases, there is a state 
of chronic inflammation. The cause of the chronic inflammation in aging is not clear. However, the 
age-related increase inflammation has been shown to impair neurogenesis by decreasing 
proliferation, survival, and integration of new born neurons. The experience dependent, 
integration and removal of neurons, appears to be important for cognitive attributes of 
neurogenesis (Aimone et al., 2009). It is plausible, that with age inflammation alters the ability of 
the new neurons to properly integrate into the existing neuronal circuit in an experience-
dependent manner. The total number of new neurons may not be the best predictor of the 
involvement of neurogenesis in age-related cognitive impairment. Alternatively, the ability of the 
new neuron to be regulated in an experience-dependent manner appears most important for the 
neural plasticity afforded by neurogenesis. The previous three chapters, demonstrated, that 
inflammation does contribute to the age-related decline in neurogenesis. Figure 19 demonstrates 
a cartoon summary of the findings of the previous three chapters. In the future, it would be 
informative to determine if restoring the inflammatory balance in humans could forestall age-
related cognitive impairments. 
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Figure 18: How neuroinflammation can modulate adult hippocampal neurogenesis.  
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